Fibroblast growth factors, A potential game plan for regeneration of skeletal muscle by Gudagudi, Kirankumar
Fibroblast Growth Factors, A potential game plan for 
regeneration of skeletal muscle. 
by 
Kirankumar Gudagudi 
Dissertation presented for the degree of Doctor of Physiological Science in 
the Faculty of Natural Science at    
Stellenbosch University 




By submitting this thesis, I declare that the entirety of the work contained therein is my 
own, original work, that I am the sole author thereof (save to the extent explicitly 
otherwise stated), that reproduction and publication thereof by Stellenbosch University 
will not infringe any third party rights and that I have not previously in its entirety or in 
part submitted it for obtaining any qualification. 
Date: December 2019 
Copyright © 2019 Stellenbosch University 




Introduction: Adult mammalian tissue regeneration recruits progenitor stem cells. In 
skeletal muscle, these are primary satellite cells. Primary satellite cells can be 
harvested from muscle tissue to investigate or even use as potential therapeutic 
application. Satellite cells exist in quiescence in the muscle tissue and only become 
activated following an insult. Most studies investigating satellite cells in vitro use 
already activated satellite cells, called myoblasts. Fibroblast Growth Factors (FGFs) 
are fundamental in embryonic development but also in adult skeletal muscle 
regeneration from injury or pathology. Understanding the role of specific members of 
this growth factor family could assist in improving the understanding of their influence 
on the regeneration sequence in skeletal muscle. 
Methods: Isolated satellite cells from human muscle biopsies were expanded in vitro 
creating primary human myoblast (PHM) clones. In order to distinguish the rate of 
proliferation between different PHM clones, a comparative index (CI) was established 
using the cell cycle and total RNA data of the two PHM clones. Two distinct index 
calculation models were also presented to determine if these may distinguish between 
the two clones with greater sensitivity. Secondly, the quiescent state is an integral part 
of stem cell regulation, therefore choosing the right protocol for inducing quiescence 
is important. In this study, two developed protocols were assessed, and a new blended 
protocol addressing the limitations of both protocols was established. This method 
involved the use of suspension culture (SuCu) with knock out serum replacement 
(KOSR). Finally, FGF6 and FGF2, both individually and sequentially, were used to 
treat quiescent myoblasts to determine their involvement in activation and proliferation 
with the use of cell cycle analysis and mRNA assessment of ki67, p21, myf5, and 
MyoD.  
Results and conclusion: The development of the CI was successful in determining the 
difference in proliferation rate for the different clones. Suspension culture with KOSR, 
the blended protocol method, resulted in reduced ki67 expression and improved 
quiescence compared to both the SuCu or KOSR alone. Unlike FGF2, individual 
treatment with FGF6 was adequate to activate the quiescent PHMs and aid their re-
entry into cell cycle with consistency in all three PHM clones by upregulating ki67 
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expression. However, FGF2 did impede the cell cycle inhibition factor p21, indirectly 
influencing proliferation. Sequential treatment of FGF6 and FGF2 allowed to determine 
whether the sequence of treatment would be important. The potential for significantly 
improving proliferation was found for the sequence: FGF6 followed by FGF2. The 
inverse sequential treatment order did not demonstrate any significant effect on both 
activation and proliferation of the quiescent cells. 
In conclusion, using clones that were distinctly different as assessed by the 
comparative index, this thesis illuminates that the two FGF family  members 
investigated, act on cell cycle in different ways, thus would influence their utilization in 




Inleiding: Regenerasie van volwasse weefsel behels die werwing van voorloper 
stamselle. In skeletspier is hierdie primêre satellietselle. Dit kan vanuit spierweefsel 
versamel word vir ondersoeke of selfs as potensiële terapeutiese aanwending. 
Satellietselle bestaan in ŉ rustoestand in die spierweefsel en word slegs na ŉ aanslag 
geaktiveer. Meeste studies wat satellietselle in vitro ondersoek, maak van reeds- 
geaktiveerde satellietselle gebruik, naamlik mioblaste. Fibroblastgroeifaktore (FGFe) 
is noodsaaklik vir embrioniese ontwikkeling, maar ook vir skeletspierregenerasie na 
besering of patologie. Om die rol van spesifieke lede van hierdie groei faktor familie te 
verstaan, kan tot verbeterde begrip van hul invloed op die regenerasie proses in 
skeletspier lei.  
Metodes: Geïsoleerde satellietselle vanaf menslike spierbiopsies is in vitro gegroei om 
primêre menslike mioblast (PMM) klone te genereer. Om die tempo van proliferasie 
tussen verskillende PMM klone te onderskei, is ŉ vergelykende indeks (VI) opgestel 
met die selsiklus- en totale RNS data van twee PMM klone. Twee afsonderlike indeks 
berekeningsmodelle is ook voorgestel om te ondersoek watter van hierdie twee 
modelle met groter sensitiwiteit tussen die twee klone kan onderskei. Tweedens is die 
metode waarmee die rustoestand geïnduseer word ŉ integrale deel van die 
rustoestand/aktivering, dus is die keuse van protokol om die rustoestand te induseer, 
belangrik. In hierdie studie was twee ontwikkelde protokolle ondersoek, asook ŉ nuwe 
verbonde protokol wat die tekortkominge van die ander twee protokolle bespreek, was 
gevestig. In hierdie metode is ŉ suspensie kultuur met uitslaan serum vervanging 
(USV) gebruik. Laastens is FGF6 en FGF2 beide individueel en opeenvolgend, 
gebruik om rustende selle te behandel om hul betrokkenheid in aktivering en 
proliferasie te ondersoek met behulp van selsiklus analise en assessering van mRNS-
vlakke van ki67, p21, myf5 en MyoD. 
Resultate en gevolgtrekking: Die ontwikkeling van die VI om die verskille in proliferasie 
tempo tussen die verskillende klone vas te stel, was suksesvol. Suspensie kultuur met 
USV, die  gemengde protokol metode, het gelei tot verlaagde ki67 uitdrukking en 
verbeterde rustende toestand in vergelyking met beide die (SuCu) of USV alleen 
(p<0.05). Anders as FGF2 was individuele behandeling met FGF6 genoeg om 
rustende PMMe te aktiveer en om hul hertoetrede tot die selsiklus te ondersteun met 
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konsekwentheid tussen al drie PMM klone deur opgereguleerde ki67 uitdrukking. 
FGF2 het egter die selsiklus inhibisie faktor p21 belemmer en so indirek proliferasie 
beïnvloed. Opeenvolgende behandeling met FGF6 en FGF2 het toegelaat dat daar 
bepaal kan word of die volgorde van behandeling belangrik is. Die potensiaal vir 
beduidende verbetering van proliferasie is gevind vir die behandelingsvolgorde: FGF6 
gevolg deur FGF2. Die omgekeerde opeenvolgende behandelingsorde het nie enige 
beduidende effek op beide aktivering of proliferasie van rustende mioblaste getoon 
nie. 
In opsomming, deur die gebruik van klone wat uitdruklik verskillend was, soos gemeet 
deur die vergelykende indeks, illumineer hierdie tesis dat die twee FGF familie lede 
wat ondersoek was, op verskillende maniere die selsiklus beïnvloed. Dit sal hul 
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Chapter 1: Introduction and literature review. 
1.1 Basic introduction to skeletal muscle and satellite cells. 
1.1.1 Skeletal muscle, physiological function and structure. 
 Skeletal muscle is one of the most important structural and functional parts of 
the body [1-4]. Located throughout the body, bundles of fibres make up the muscle 
tissue. Skeletal muscle is comprised of long muscle fibres which are generally 
consistent in shape although they may differ in diameter depending on the typical 
function [5]. Typically, muscle fibres contain multiple elliptical nuclei in each cell and a 
homogeneous cytoplasm deriving from up to hundreds of muscle progenitor cells. 
Skeletal muscle is one of the three major muscle types in the human body [6]. Skeletal 
muscle, cardiac muscle and smooth muscle. Physiological functions of skeletal muscle 
include, differs in that it is used for voluntary movement and plays an important role in 
energy metabolism and storage. Cardiac muscle helps the heart move the blood from 
the heart to the vascular system aiding in proper oxygenation of all the cells in the 
body. Smooth muscle on the other hand is involved in multiple organ systems in an 
involuntary fashion, shortening in order to either propel various contents in the lumen 
of the organs or to keep an opening closed [6]. Skeletal muscle cells (fibres) create 
the most force. A single skeletal muscle can contain hundreds of individual muscle 
fibres bundled together within connective tissue called epimysium. Skeletal muscle 
varies in size, shape and arrangement of fibres depending on localization. For 
example, individual muscle fibres can be thin but total muscle mass can be large as 
seen in the gastrocnemius muscle. Skeletal muscle fibres are fragile when exposed to 
high contractile forces. In particular, skeletal muscles are attached via tendons at both 
proximal and distal tips to bones, the contractions allow for movement of attached 
bone elements and which increases the inherent risk of damage but also damage can 
occur from trauma or disease. They are prone to constant damage and regular 
regeneration. Figure 1.1 illustrates the structure of skeletal muscle in vivo and the 
various components each of which is generated from different progenitor cell types. 
The muscle is encapsulated in a connective tissue sheath called as epimysium. The 
bundle of each muscle fibre is called as a fasciculus and is covered by another 
connective tissue known as perimysium. Furthermore, each individual muscle cell 





the bundle of muscle cells within epimysium is connect to the bone by a connective 
tissue called as tendon. 
 
Figure 1.1 Structure of Skeletal Muscle in vivo [7] 
 
1.1.2 Satellite cells: their quiescence and activation 
  The study of satellite cells or muscle stem cells can be dated back to 1961 when 
they were identified by Alex Mauro [8] using electron microscopy. Satellite cell 
numbers peak at about 30-35% of total muscle cells during the neonatal stage [9-13]. 
Satellite cells are highly active during this early stage of development to facilitate the 
rapid gain in muscle mass [9, 14-16]. In adulthood they stabilise at approximately 2-
7% of the total muscle cells [10-13, 17]. These cells reside in a quiescent state, 
between the basal lamina and sarcolemma of the muscle fibre and express specific 
genes resulting in identifiable mRNA and protein markers such as Pax7, Pax3, CD34, 
M-cadherin, syndecan-4 and CXCR4 [18-20].  
In adults, muscle regeneration is a complex and time-consuming process involving 
numerous stages [21-24]. Starting with the activation of individual skeletal muscle 
progenitor cells (also called satellite cells), followed by their proliferation, differentiation 





activated by damage and participate in regeneration, including fibroblasts. However, 
satellite cells are the main contributors [17, 25]. 
Quiescent satellite cells are multipotent cells with a high nucleus to cytoplasm ratio 
and a large quantity of heterochromatin [26]. Satellite cells are proficient and essential 
stem cells for skeletal muscle regeneration, which has been demonstrated by lineage-
tracing, cell ablation and cell transplantation studies [27-33]. Upon activation, they re-
enter the cell cycle and have the potential to fuse to their adjacent myofibre thus 
providing additional nuclei to the myofiber, or else return to the quiescent state in which 
they maintain their stem cell characteristics. Following activation, the satellite cells 
become spindle-shaped and have decreased levels of heterochromatin and an 
increased number of cytoplasmic organelles. Due to their usual quiescent nature, 
satellite cell activation is a crucial step in skeletal muscle regeneration [34]. 
Entry into the cell cycle, in response to tissue damage, occurs under the influence of 
several activation factors including hepatocyte growth factor (HGF) [35], fibroblast 
growth factors (FGF) [36] and platelet derived growth factor (PDGF) [37, 38]. The 
damage may be acute or chronic. For example, following acute injury of muscle tissue, 
HGF is typically highly elevated, whilst with chronic damage leading to necrosis of 
muscle tissue, FGF6 is upregulated [39]. These factors have been added to satellite 
cells cultures to determine their effects on proliferation and differentiation, however, 
satellite cells in culture are typically already activated, which is not the case in vivo.  
Before undergoing myogenic differentiation, activated satellite cells proliferate and 
begin to express low levels of myogenic regulatory factors (MRFs), at which time they 
are called myoblasts. The earliest markers associated with satellite cell activation are 
phosphorylated-p38 mitogen-activated protein kinase (p38 MAPK) followed by MyoD 
[39-41]. The earliest markers indicating a switch to a more differentiation-prone 
phenotype is higher MyoD expression and the expression of the MRF, myogenin, and 
the cytoskeletal protein, desmin [8] . This myogenic differentiation step preceeds 
fusion whereby satellite cells provide additional nuclei to the existing myofibers [42] 






Figure 1.2 Illustration of Skeletal muscle satellite cells and its function originally 
published by Yin H (2013) [26] 
 
1.1.3 Primary satellite cells 
Although skeletal muscle regeneration has been extensively studied both in vitro and 
in vivo, a main focus was on factors promoting proliferation (in vitro) and the post-
fusion myonuclear counts (in vivo). Also, the overwhelming majority of research was 
completed using an immortalised cell line (the C2C12 cells) and although the data 
generated advanced understanding in this field, it does not adequately represent 
primary satellite cells harvested directly from excised adult tissue.  
Primary cells are derived from tissue samples from living donors. Since donors have 
different genetic variability, physiological states and may have adapted distinctly to 
living conditions prior to tissue harvesting, there is a significant heterogeneity in the 
primary cells isolated from different individuals. This heterogeneity could be further 
exacerbated by varying abilities to adapt to cell culture conditions. This complicates 
the use of primary myoblasts in the research setting and hence requires protocols to 
establish a more uniform baseline. Establishing uniform baseline conditions is 
important for at least two reasons: to assess inherent individual variability that is not 
simply due to harvesting protocols, and to more effectively evaluate the effects of a 
subsequent experimental intervention.  
Taking into account the arguments set out above and recent advances in techniques, 
this thesis addresses both of these issues in the following ways: the study of primary 





Specifically, this thesis developed a novel protocol to compare the proliferative 
capacity of primary human myoblasts from different donors (comparative index). 
Further, compared two distinct in vitro protocols to induce quiescence. Thereafter, a 
blended protocol of both was designed and tested. Finally, the influence of FGFs on 
activation of satellite cells following induced quiescence was studied, specifically 
focusing on FGF6 and FGF2. The following sections in this chapter (1.2 to 1.4) gives 
the brief explanations of what the experimental chapters contain.   
 
1.2 Comparative index of isolated PHMs 
  As previously discussed, primary cells are derived from tissue samples from 
living donors, who may have adapted distinctly to living conditions prior to tissue 
harvesting. Since there is significant heterogeneity in the primary cells isolated from 
different individuals prior to experimental intervention, it is important to understand and 
quantify individual variability. Surprisingly, there are no clearly defined protocols 
currently available to assess the characteristics of primary cells in vitro in a 
comparative manner. Also, when performing in vitro experiments during which cells 
are exposed to treatments that affect cellular and molecular function, a key aspect 
would be to establish a baseline characteristic which could then be used to compare 
the responses to the various treatments or interventions in the future. This part of the 
thesis aimed to establish a baseline index with which primary human myoblasts can 
be compared to each other. 
 
1.3 Comparison of two distinct in vitro quiescence protocols and induction of 
novel blended protocol.  
  Transforming cells in vitro into a state of quiescence is a relatively new 
technique and allows the progression from quiescence to activation to be studied in 
greater detail. In chapter 4, two established protocols to promote cellular quiescence 






1.3.1 In vitro quiescence using suspension culture 
  In order for primary human skeletal muscle cells (PHMs) to proliferate and 
differentiate in vitro, they require some cell to cell contact for certain types of 
intracellular communication and cell to surface contact for anchoring. Depriving 
immature cells of these two factors tend to guide them towards reversible cell cycle 
exit and this can be achieved by individual cell suspension in a semi-solid medium 
(2% methyl cellulose) [43]. For example, methyl cellulose suspension of PHMs has 
been shown to permit cell separation and reduce aggregation or the settling of cells to 
the bottom of the media. 
 
1.3.2 In vitro quiescence using knock-out serum replacement (KOSR)  
  Foetal bovine serum (FBS) is a well-known media supplement for cell culture. 
FBS is composed of a heterogenous mixture of proteins, hormones, macromolecules 
and other chemical components which promote cell survival and proliferation. 
KOSR however, is a synthetic serum replacement cocktail that supports growth of 
pluripotent stem cells but lacks components that stimulate proliferation. Previous work 
in our group found that culturing of PHMs in Ham’s F10 nutrient media with KOSR for 
10 days without any additional supplementation, stimulated cells to reversibly exit the  
cell cycle [44]. 
 
1.3.3 Development of a novel blended protocol to achieve improved quiescence. 
  Given that suspension culture provides quiescence and KOSR replacement 
cocktail also promotes quiescence, replacing FBS with KOSR in the suspension 
culture could potentially provide an improved state of reversible quiescence in PHMs, 
compared to either method or alone. 
 
1.4 Fibroblast growth factors (FGFs). 
  FGFs are a family of cell signalling proteins that bind to heparin or heparin 
sulphate and regulate a broad spectrum of biological functions, including cellular 





leads to developmental defects. In humans, FGF is a 22-member family signalling 
through four FGF receptors (FGFR-1 to FGFR-4) [46-48]. The canonical FGFs are 
secreted proteins and the receptors are located on the surfaces of the cell. The 
receptors contain three extracellular immunoglobulin-type domains (D1-D3) and a 
single intracellular tyrosine kinase domain for activating downstream cascades such 
as PI3K/AKT, MAPK and STAT. Phylogenetic analysis of the FGFs suggests that the 
22-member family can be classified into seven smaller sub-families of two to four 
members each. The analysis of the FGFs also suggests that the sub-families 
FGF1,4,7,8 and 9 are involved in encoding secreted canonical FGFs which function 
by binding and activating FGFRs with heparin or heparin sulfate as a cofactor [49]. 
Within the sub-families, the individual FGFs were numbered according to their 
discovery. Importantly, satellite cells /myoblasts have been shown to have high affinity 
to heparin sulfate proteoglycan receptors of FGF [50]. During muscle regeneration, 
increase in heparin sulfate proteoglycans and the requirement of syndecan-3 for 






Figure 1.3 The FGF superfamily and subclassifications of Fibroblast Growth Factors. 
Boxes around FGF indicate importance for myoblast biology. [Modified from [49]] 
 
1.4.1 Introduction to Fibroblast growth factor 2  
  FGF 2 also known as bFGF or basicFGF, is a signalling protein first purified in 
1975 [52]. It is a critical growth factor for embryonic stem cells to remain in an 
undifferentiated state in culture [53]. In humans, FGF2 has a protein weight of 18 kDa. 
It is a 155 amino acid polypeptide that binds to fibroblast growth factor receptors. Like 
other members of the FGF family, FGF2 has broad mitogenic properties and 
influences many biological processes like embryonic development, cellular 
proliferation and tissue repair .  
Normally, FGF2 is located in basement membranes and in the subendothelial 
extracellular matrix of blood vessels [54]. Following activation of the wound healing 





response to injury suggests that FGF2 has an important role to play in processes 
occurring specifically in the early phases  [45].  
FGF2 is widely used in regeneration of soft tissue [45, 54, 55]. PI3k/Akt is an 
intracellular signalling pathway important for cell cycle progression. A recent study 
involving bovine endometrial cells reported that FGF2 induces proliferation and 
distribution of cells in the G2 /M phase and that activation of PI3K/Akt cell signalling 
occurs [48]. Thereafter some regulation of cyclin D1 is by miR-1 and miR-133 which 
are primarily tumour suppressors. However, miR-133 in specific has been reported to 
play a feedback mechanism using ERK1/2 pathways regulating myoblast proliferation 
and differentiation [56].  
Cyclin D1 expression is essential for cell cycle progression. Elevated FGF2  has been 
shown to attenuate p38 mediated miR-1/133 expression and subsequent upregulation 
of Sp1 (specificity protein 1)/Cyclin D1 which increases myoblast proliferation during 
early stage of muscle regeneration [57]. Similarly, in a study performed in vivo (murine 
model) as well as in vitro on Sca-1+ cardiac muscle stem cells revealed FGF2 as an 
essential molecule in cell migration. However, endogenous FGF2 levels observed in 
the in vitro model were not adequate to be effective for aiding regeneration of the 
tissue in the case of myocardial infarction. When provided with exogenous FGF2, the 
cardiac muscle cell migration was greatly improved through activation of the PI3K/Akt 
pathway [58].  
In an in vivo study that aimed to evaluate the role of myoblasts in recovery and 
regeneration of injured muscle tissue, Sprague-Dawley rats with thigh muscle injury 
were transplanted with GFP-positive myoblasts. Four weeks after the transplant the 
GFP-positive cells were found to be integrated into the damaged area. Their 
contribution to the regeneration of the tissue was shown by Hagiwara  et al (2016) 
[59]. Thereafter, the efficacy of myoblast transplantation in combination with controlled 
and sustained delivery of FGF2 was investigated. This strategy resulted in promotion 
of muscle regeneration [59].  
In agreement with the literature [60] the preliminary work on primary human myoblasts 
with FGF2 indicated an increase in the rate of proliferation. Active myoblasts treated 





supplementation. This work on myoblasts correlates with findings from other research 
suggesting FGF2 promotes proliferation of myoblasts [61-63].  
 
1.4.2 Introduction to Fibroblast growth factor 6 
  FGF6 is one of the FGF family members predominantly found in cells of 
myogenic lineage suggesting a role in muscle development [64]. The FGF6 gene 
encoded in humans has comparable properties to FGF2 in terms of cell growth, tissue 
repair and embryonic development. However, subtle and less subtle differences have 
been shown with FGF6 being the key ligand for FGFR4 as well as being known to be 
important in initiation and regulation of osteoblasts [65]. Indeed, there is evidence that 
FGF6 has dual functions in muscle, influencing regeneration as well as 
differentiation/hypertrophy in a dose dependent manner using distinct pathways 
employing either FGFR1 or FGFR4 [66]. During muscle necrosis FGF6 was released 
from necrotic myofibers and then sequestered in the basal laminae [67]. Due to the 
position of satellite cells just under the basal lamina, this could be the mechanism that 
initiates the activation of quiescent satellite cells and to aid the rescue. One particular 
study looking at FGF2/FGF6/mdx triple mutant mice found that FGF6 mutant 
myoblasts did have reduced ability to migrate in vivo [68]. These studies support the 
initiation side of the FGF6 in regeneration [69, 70].  
Compared to FGF2, studies investigating FGF6 are limited, therefore, understanding 
the relationship of FGF6 to skeletal muscle regeneration in the adult setting requires 
further investigation. 
 
1.4.2.1 FGF6, debate on activation of quiescent cells. 
 In a study published by Floss et al in 1997, the function of FGF6 in skeletal 
muscle regeneration was investigated using FGF6 (-/-) mice [69]. The global 
inactivation of the FGF6 gene severely impaired muscle regeneration, reducing 
MyoD+ and myogenin+ satellite cell number. The quiescent satellite cell pool was 
remained unaffected. Therefore, the activation or proliferation process was impaired. 
The authors concluded that FGF6 plays an integral role in the skeletal muscle 





On the contrary a similar study conducted by Fiore et al in 2000 suggested that 
“skeletal muscle regeneration is not impaired [70]” using FGF6 (-/-) mutant mice. The 
FGF6 inactivation was achieved by targeting the FGF6 gene by using a replacement 
vector [70]. Muscle degeneration was achieved by addition of notexin drug or crush 
injury, after which the defect in the gene did not seem to affect the muscle 
regeneration.  
Comparing the two studies, one could see the similarity in the strategy employed in 
both investigations to achieve FGF6 (-/-). In the study conducted by Floss et al, 
homologous recombination was employed to inactivate the FGF6 gene in embryonic 
stem cells by utilising a vector to target the FGF6 gene and replace 3.8kb of genomic 
content. The inactivation resulted in complete inhibition of the gene. This resulted in 
MyoD- and myogenin- satellite cells resulting in incomplete regeneration.  
Following the study by Fiore et al, a similar strategy was employed to target the FGF6 
gene in the embryos by vector, and homozygous disruption of FGF6 gene was 
achieved. However, the regeneration of skeletal muscle was studied further by 
breeding with C57BL/6 females. Southern blot evaluation revealed FGF(+/-) 
heterozygous mice having apparent normal phenotype. Furthermore, the F2 
generation was obtained by mating heterozygous males with heterozygous females 
and later southern blot analysis was found to follow mendelian distribution. Although 
further evaluation states FGF6’s absence in regeneration, the complex study design 
does not clearly illustrate achieving FGF6 inhibition. With F1 and F2 generations both 
presenting FGF6(+/-) genes, it demonstrates that a single dominant allele with FGF6 
could be sufficient to maintain normal muscle regeneration.  
The in vivo studies are complicated and often regeneration could be assisted by other 
functions or role players. An advantage of in vitro work is that a single treatment can 
be applied directly. The in vitro treatment method allows a clear assessment of the 
treatments’ individual specific action on the cells as there would be no additional 






1.4.3 Introduction to FGF2 and FGF6 as treatments. 
  FGF2 has been applied in recent clinical trials investigating angiogenesis and 
tissue regeneration in various adult tissues [71] (Table 1) . Owing to the pro-
proliferative effect of FGF2, it has been used to enhance the precursor cell population 
numbers. In vivo skeletal muscle regeneration begins with the activation of quiescent 
satellite cells. Although it has been suggested that FGF2 might help in activating 
quiescent satellite cells in rodent models [72], this has been eclipsed by focus on 
proliferation.  
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FGF6 has been linked predominantly to the myogenic lineage during development 
suggesting that FGF6 might hold significant value in the regeneration sequence which 
replicates the development process. With limited information available about the 





combined both growth factors to determine whether activation / proliferation could be 
improved if used in combination. 
The experimental plan involved applying a treatment regimen of FGF6 and FGF2 in 
sequence to actively proliferating PHMs as well as to KOSR-treated quiescent PHMs. 
Assessment involved cell cycle analysis concentrating on the G0/G1 phase to S phase 
transition and qPCR analysis of key markers genes of activation and proliferation, i.e. 
ki67, p21, myf5 and MyoD.  
 
1.4.4 Significance of ki67, p21, myf-5 and MyoD. 
  ki67 also known as MKI67 is a protein encoded by the MKI67 gene in humans 
found on chromosome 10 [74]. It is a nuclear protein that is associated with cellular 
proliferation and ribosomal RNA transcription and is present in each phase of the cell 
cycle (G1, S, G2 and M). During interphase, the ki67 antigen is located exclusively 
inside the cell nucleus, while during mitosis the protein is located on the surface. This 
suggests that the main role is during cellular proliferation and it can therefore be used 
as a marker for proliferation [75].  
Cyclin-dependent kinase inhibitor 1, also known as p21 is an important regulating 
factor in the cell cycle. It is encoded by the CDKN1A gene found on chromosome 6 in 
humans [76]. The regulation of cell cycle progression involves inhibiting the CDK2 
complex at G1 and S phase [77]. Studies investigating CDK2 activity have shown that 
the expression level of p21 in the cell could be responsible for the bifurcation in CDK2 
which in turn could be involved in regulating proliferation or attaining G0/quiescent 
state [78]. 
The myf5 protein is encoded by MYF5 gene in humans with the key role associated 
with myogenesis and regeneration. Located on chromosome 12, myf5 belongs to the 
group of myogenic regulatory factors (MRFs. The loss of MyoD and myf5 has been 
shown to result in altered skeletal muscle programming and failed regeneration [79]. 
The muscle-specific gene myf5 plays a critical role in embryonic and foetal 
myogenesis. Expression of myf5 has been studied and linked to ultimately giving rise 





Myoblast determination protein 1, more commonly known as MyoD, is a transcription 
factor of the MRF family. Discovered and characterised by Weintraub’s lab, MyoD is 
well known to be associated with myogenesis [81]. Since the discovery, MyoD has 
been the gold standard identification marker for myoblasts. The potency of MyoD was 
well recognized when it was proved that MyoD could convert fibroblasts to myoblasts 
[81, 82]. Both MyoD and myogenin are seen co-expressed in differentiating myoblasts 
in regeneration of injured skeletal muscle tissue [83] and its expression is absent from 
quiescent satellite cells. In contrast, myf5 discussed above is expressed in quiescent 
cells (Partridge T) and hence these two MRFs can be used as markers distinguishing 
how far myoblasts are in the path from quiescence to differentiation.  
 
1.4.5 Aims and objectives 
  The background information regarding the gaps in the published research 
discussed above brings us to the aims and objectives of the research.  
Aim 1: Establish a comparative index. 
Objectives: 
1. Establish a new protocol to compare primary human myoblasts in vitro. 
2. The protocol should use the rate of proliferation and at least one other 
phenotypic characteristic that is likely to be adaptable to treatments. 
3. Establish a mathematical model which can be used to explain the 
difference between cells derived from different donors. 
Aim 2: Comparison of two in vitro quiescence protocols to choose the right 
quiescent method for future experiments and to determine if a blended protocol 
would differ from either or both of the specific protocols. 
Objectives: 
1. Compare induction of quiescence using SuCu and KOSR by assessing 
effects on cell cycle genes. 






3. Replace FBS in SuCu with KOSR to investigate if this changes the 
induction of quiescence. 
Aim 3: Understanding the role of FGF6 and FGF2 in activation and proliferation 
of PHMs. 
Objectives: 
1. Establish quiescence in all the PHM clones to be used. 
2. Assess the activation potential of FGF6 in quiescent PHMs 
3. Assess the activation potential of FGF2 in quiescent PHMs 
4. Assess activation and proliferation of quiescent PHMs using sequential 
treatment of FGF6 followed by FGF2 
5. Assess activation and proliferation of quiescent PHMs using inverse 






Chapter 2: Materials and methods 





Bovine Serum Albumin (BSA) 10735086001 Roche Holding AG, Basel, 
Switzerland 
Cell counter counting chamber 
slides 
C10228 Thermo Fisher Scientific, 
Massachusetts, USA 
Cell culture Flask, 175m2 709003 Nest Biotechnology Co.,Ltd, 
Jiangsu, China 
Cell culture Flask, 75m2 708003 Nest Biotechnology Co.,Ltd, 
Jiangsu, China 
Cell culture Flask, 25m2 707003 Nest Biotechnology Co.,Ltd, 
Jiangsu, China 
Cell culture Plate 6- well 703001 Nest Biotechnology Co.,Ltd, 
Jiangsu, China 
Cell cycle kit BD BD/340242 Becton Dickinson, New Jersey, 
USA 
Cell tracker C2925 Thermo Fisher Scientific, 
Massachusetts, USA 
Chloroform C2432 Sigma-Aldrich (Pty) Ltd, Missouri, 
USA 
Dimethyl Sulfoxide C6164 Sigma-Aldrich (Pty) Ltd, Missouri, 
USA 
DMEM 11965092 Thermo Fisher Scientific, 
Massachusetts, USA. 
E-C-L cell attachment matrix 
(Entactin- collagen IV-laminin) 
11965092 MilliporeSigma, Massachusetts, 
USA. 






Ethyl alcohol E7023 Sigma-Aldrich (Pty) Ltd, Missouri, 
USA 
Fetal Bovine Serum 10438026 Thermo Fisher Scientific, 
Massachusetts, USA 
Glutamax 35050061 Thermo Fisher Scientific, 
Massachusetts, USA 




Sigma-Aldrich (Pty) Ltd, Missouri, 
USA. 
Hoescht 62249 Thermo Fisher Scientific, 
Massachusetts, USA 
Isopropanol I9516 Sigma-Aldrich (Pty) Ltd, Missouri, 
USA 
KOSR (KnockOut™ Serum 
Replacement) 
10828010 Gibco™, Thermo Fisher 
Scientific, Massachusetts, USA 




15070063 Gibco™, Thermo Fisher 
Scientific, Massachusetts, USA 
Phosphate Buffered Saline 
tablets 
P4417 Sigma-Aldrich (Pty) Ltd, Missouri, 
USA 
qPCR Gene primers  Integrated DNA Technologies - 
Iowa, USA. 
rh-FGF2 protein PHG0266 Gibco™, Thermo Fisher 
Scientific, Massachusetts, USA 
rh-FGF6 protein PHG0174 Gibco™, Thermo Fisher 
Scientific, Massachusetts, USA 
SYBR™ Select Master Mix 4472908 Thermo Fisher Scientific, 
Massachusetts, USA 






Trypan blue 0.4% 15250061 Thermo Fisher Scientific, 
Massachusetts, USA 
Trypsin 0.25% EDTA 25200072 Thermo Fisher Scientific, 
Massachusetts, USA 
0.22 µm filter syringe  MilliporeSigma, Massachusetts, 
USA. 
Methods: 
All in vitro experimentation was performed under sterile conditions in a BSL2 
laminar flow hood, unless otherwise stated. In Chapter 2, general methods used to set 
up the subsequent experiments are described. Specific methods are discussed in the 
relevant chapters (3, 4, 5) along with a brief introduction and the results. 
 
2.1 Media and buffer preparation  
2.1.1 Preparation of Phosphate Buffered Saline 1x (PBS) 
 PBS tablets (cat # P4417, Sigma-Aldrich (Pty) Ltd, Missouri, USA)  were used 
to prepare 1xPBS solution in deionized water. According to the manufacturer 1 PBS 
tablet provides 200 ml of 1x PBS. 1 Tablet was placed in a clean glass bottle with 50 
ml of deionized water and swirled until the tablet completely dissolved, dH2O was 
added to make the final volume 200 ml. The solution was then autoclaved at 121˚C 
for 30 min to obtain sterilized 1x PBS for cell culture use. 
 
2.1.2 Proliferation Media (PM) 
 Proliferation media was prepared using Ham’s F10 (cat # N6908, Sigma-Aldrich 
(Pty) Ltd, Missouri, USA) nutrient mixture, containing high glucose and L-Glutamine. 
Ham’s F10 was supplemented with 20% FBS (cat # 10438026, Thermo Fisher 
Scientific, Massachusetts, USA) and 1% penicillin/streptomycin (PenStrep) (cat # 
15070063, Gibco™, Thermo Fisher Scientific, Massachusetts, USA). The mixture was 
then filtered through 0.22µm filter using a syringe (cat # SOGV033RS , MilliporeSigma, 
Massachusetts, USA). aliquoted into 50 ml tubes and stored at 4˚C. Media was stored 






2.1.3 Quiescence Media (QM) 
 Quiescence media was prepared using Ham’s F10 nutrient mixture 
supplemented with 20% knockout serum replacement (KOSR) (cat # 10828010, 
Gibco™, Thermo Fisher Scientific, Massachusetts, USA ) and 1% PenStrep. KOSR is 
a defined FBS-free medium supplement that supports growth of stem cells. The 
mixture was aliquoted into 50 ml tubes and stored at 4˚C. Media was stored for a 
maximum of 4 weeks. This mixture will henceforth be called as Quiescent media (QM). 
 
2.1.4 Suspension culture media (SuCu) 
The suspension culture media (SuCu) consisted of 2% sterilized methyl 
cellulose (cat # M0512, Sigma-Aldrich (Pty) Ltd, Missouri, USA) in Dulbecco’s modified 
eagle medium (DMEM) (cat # 11965092, Thermo Fisher Scientific, Massachusetts, 
USA). The solution was heated to 50 ˚C and stirred overnight prior to storage at 4˚C. 
   
2.1.5 Differentiation Media (DM) 
 Differentiation media was prepared with DMEM containing high glucose with L-
Glutamine supplemented with 1% Equine serum (cat # 16050122, Thermo Fisher 
Scientific, Massachusetts, USA) and 1% PenStrep. The mixture was then filtered 
through 0.22 µm filter using a 50 ml syringe. aliquoted into 50 ml tubes and stored at 
4˚C. The solution was stored maximum for 4 weeks.  
 
2.1.6 Freezing Media (FM) 
 Freezing media was prepared using 10% DMSO (cat # C6164, Merck, New 
Jersy, USA) and 90% FBS. The solution was prepared when required just before 
freezing the cells and not stored. The volume of freezing media was prepared 
according to the number of cells being frozen. A concentration of 1x10^6 /ml was 






2.1.7 Entactin-collagen IV-laminin (ECL) preparation.  
 Entactin-collagen IV-laminin (cat # 11965092, MilliporeSigma, Massachusetts, 
USA) solution with the final concentration of 20 µg/ml was prepared in PBS.  
 
2.1.8 Preparation of 0.1% Bovine Serum Albumin (BSA) 
 10 mg of BSA fraction (cat # 10735086001, Roche Holding AG, Basel, 
Switzerland) was dissolved in 5 ml PBS, once completely dissolved PBS was added 
to make the final volume 10 ml to obtain a final concentration of 0.1%. The solution 
was then sterile filtered using 0.22 µl syringe filter inside laminar airflow. The BSA 
solution was prepared just before preparing stock solutions.  
 
2.1.9 Preparation of recombinant human Fibroblast Growth Factor 2 (rh-FGF2) 
Stock solution 
Lyophilized rh-FGF2 vial (25 µg) (cat # PHG0266, Gibco™, Thermo Fisher 
Scientific, Massachusetts, USA) was briefly centrifuged before opening. 25 µg of rh-
FGF2 was dissolved in 2.5 ml of 1x PBS. As per manufacturers recommendations, rh-
FGF2 was reconstituted at a stock concentration of 10 ng/µl in 1x PBS, 50 µl aliquots 
were prepared and stored at -80˚C. 
 
2.1.10 Preparation of recombinant human Fibroblast Growth Factor 2 (rh-FGF2) 
working solution. 
 Stock solution of FGF2 (10 ng/µl) was added to the required media (PM or QM) 
to obtain the final concentration of 10 ng/ml of media (1 µl of stock to 1 ml of media). 
 
2.1.11 Preparation of recombinant human Fibroblast Growth Factor 6 (rh-FGF6) 
stock solution. 
 Lyophilized rh-FGF6 vial (25 µg) (cat # PHG0174, Gibco™, Thermo Fisher 
Scientific, Massachusetts, USA) was briefly centrifuged before opening. 25 µg of rh-





rh-FGF6 was reconstituted at a stock concentration of 10 ng/µl in 0.1% BSA, 10 µl 
aliquots were prepared and stored at -80˚C.  
2.1.12 Preparation of recombinant human Fibroblast Growth Factor 6 (rh-FGF6) 
working solution. 
 Stock solution of rh-FGF6 (10 ng/µl) was added to the required media (PM or 
QM) to obtain the final concentration of 10 ng/ml of media (1 µl of stock to 1 ml of 
media) 
 
2.2 Procedures and protocols 
 
2.3.1 Coating of Culture Plates with ECL 
 ECL was brought to 37˚C in a water bath and enough solution was added to 
cover the culture area generously (consult table 2.1). The plate was then incubated 
either at 4˚C overnight or for 2 hours at 37˚C in the incubator. The excess ECL was 
either discarded or used immediately to coat another plate. The excess ECL was only 
removed just before plating of the cells. Reusing of the ECL was performed only once. 
Table 2.1 ECL for coating culture dishes 
Plate / Flask size Volume of ECL 
12 well plate – per well 500 µl 
6 well plate – per well 1 ml 
t25 2 ml 
t75 3 ml 
t175 7 ml 
 
Note: All culture plates and culture flasks further described were observed under 
microscope every time they were taken out of incubator.  
Media Change: After removing the previous media present in the flask and 





previously in the flask or the new required media) and placed in the incubator, unless 
otherwise stated. This procedure will further be referred to as changing media. 
 
2.3.2 Procurement of PHMs 
2.3.2.1 PHM isolation 
Excess tissue from muscle biopsies from Vastus Lateralis of human subjects 
were generously provided by Greig Thomson, Jason Lovett (ethics number 
S17/03/061) and Cameron Sugden (ethics number S17/10/240) after these 
researchers had cut samples to a shape suitable for histology. The biopsies were 
about 100 mg and 3-5 mm in diameter before dividing according to purpose. The 
portions for isolation of satellite cells were transported from the clinical room to the 
culture laboratory in ice cold PBS with 10% PenStrep and 1% Gentamycin.  
 The tissues were dissected into about 3 mm2 square pieces on a sterile glass 
slide inside a 10 cm sterile petri dish, repeatedly washed in fresh ice-cold PBS and 
plated on to a 12 well culture plate coated with ECL. Tissues were incubated with 300 
µl proliferation media for 24 hours at 5% CO2 and at 37˚C. After 24 hours, additional 
1 ml of proliferation media was added gently to the wells without disturbing the tissues 
and incubated again for 24 hours. Media was then changed after a further 24 hours. 
On day 4, the tissue was aspirated and placed in a new well coated with ECL and 300 
µl of media was added carefully. The culture was continued with media changes every 
48 hours and the transfer of the tissue to a new coated well every 3-4 days for 18 days 
to selectively separate fibroblasts from late migrating myoblasts. As fibroblasts migrate 
from the tissue in the early stages, the period from 14-18 days represented the time 
when the majority of cells separated from the tissue samples were myoblasts.  During 
this period (or at 18 days?), a small portion of each well containing almost exclusively 
myoblasts was demarcated using an insert and trypsinised. The cells harvested from 
this partial trypsinisation were replated and subjected to  differentiation conditions to 
assess the successful formation of myotubes to verify the validity of the isolated 
myoblasts (see next section). Remaining adherent cells were trypsinsed with 0.5% 
EDTA trypsin (cat # 25200072, Thermo Fisher Scientific, Massachusetts, USA) and 





actively proliferating and confluent, the cells were trypsinised and transferred to larger 
culture dishes for expansion.  
 
2.3.2.2 Confirmation of myoblast phenotype  
The partially trypsinised PHMs were proliferated to 90% confluency and the 
media was changed to DM. The culture was continued for 5 days. Cell tracker with 
nuclear staining was performed to identify multinucleated tubes. Hoescht (cat # 62249, 
Thermo Fisher Scientific, Massachusetts, USA) 1:200 dilution and cell tracker (cat # 
C2925, Thermo Fisher Scientific, Massachusetts, USA) 1:1000 dilution in proliferation 
media was used to prepare the staining solution with final volume of 3ml. 5 min before 
the imaging, the staining solution was added to the well inside the hood and incubated 
at 37˚C and imaging was performed on Nikon ECLIPSE E400 microscope. The same 
differentiation was confirmed with all the PHM clones used in the studies. 
 
 
2.4.1 Suspension culture protocol 
The suspension culture was prepared by combining the SuCu with 20% FBS, 4 mM 
Glutamax (cat # 35050061, Thermo Fisher Scientific, Massachusetts, USA), 0.1% 
PenStrep and 1M HEPES (cat # 7365-45-9 H4034, Sigma-Aldrich (Pty) Ltd, Missouri, 
USA). All components were pre-warmed to 37˚C whilst the latter components were 
prepared and filtered separately from the SuCu, prior to mixing. PHMs (1 million/ml) 
Figure 2.1 Representative image of multinucleated 





were added to the suspension culture in a slanted tube and were mixed gently for 5-
10 min by rotating the tube. Thereafter, the tube was incubated for 24 hrs at 37˚C with 
5% Co2 in an incubator and gently mixed again by rotating the tube and then incubated 
for 24 hrs more. The composition of the suspension culture is summarized below 
  10 ml Suspension culture. 
   2 % Methyl cellulose  - 6.70 ml 
   20 % FBS   - 2 ml 
   4 mM Glutamax  - 100 µl 
   PenStrep   - 100 ul 
   1M HEPES   - 100 ul 
   Cells 1 million /ml  - 1 ml 
 
2.4.2 Cell culture and passaging  
Cell culture was performed in a laminar flow with sterile techniques. All required 
media, PBS and Trypsin were brought to 37˚C before being used for cell culture. For 
culturing PHMs, the culture dish was coated with ECL as previously discussed. 
Passaging was performed when the cells proliferated to about 70% of the culture dish 
used. Media was removed followed by two washed with 1x PBS and subsequent 
trypsinization. Trypsin-EDTA (1X, T3924) was used to dislodge cells from the surface 
of the culture dish (refer to table 2.2 for volume of trypsin used). Preheated media was 
used to deactivate the trypsin and the cells were collected in a falcon tube. 
Centrifugation was performed at 325 g at 22˚C for 3 min. Supernatant was discarded. 
1 ml of fresh media was added and triturated to get uniform single cell suspension. 











Table 2.2 Volume of trypsin for Trypsinization 
Plate / Flask size Volume of Trypsin 
12 well plate – per well 125 µl 
6 well plate – per well 250 µl 
t25 500 µl 
t75 1.5 ml 
t175 3.5 ml 
 
2.4.3 Partial trypsinisation (Trypsin inserts) 
 Inserts were prepared using a 25 ml serological pipette (Figure 2.2, 2.3). 
Approximately ½-1 cm was cut from both ends using microtome knife. The inserts 
were then cleaned under naked flame to burn any plastic residue. The inserts were 
sterilized in 70% ethanol overnight and washed serially in 1x PBS before use. 
 
 
Figure 2.3 25 ml serological pipette 
marked for separation 
Figure 2.3 Inserts separated from the 





The culture well was divided into 45˚ angles and marked underneath the plate. The 
area of trypsinization was chosen by observing under the microscope. In the laminar 
flow, the dish was washed twice with PBS and the inserts were placed in the region 
chosen. While holding the insert with sterile forceps, 50 µl of trypsin was added and 
incubated for 2-3 min (Figure 2.4, 2.5). Once cells began to lift from the culture surface, 
the trypsin (containing cells) was aspirated and placed in an 1.5 ml Eppendorf tube. 
50 µl of media was then added inside the insert to collect the remaining dislodged 
cells.  
                            
2.4.4 Cell counting using automated cell counter (Countess II, Thermo 
Scientific™)  
Using 1:1 mixture of 0.4% trypan blue (cat # 15250061, Thermo Fisher 
Scientific, Massachusetts, USA)  and cell suspension, 10 µl was loaded onto 
disposable cell counter slides (cat # C10228, Thermo Fisher Scientific, 
Massachusetts, USA). The slide was then loaded on to the automated cell counter, 
focused using coarse and fine adjustments and cell were counted. Instrument reading 
of live cell, dead cell, total cell count and cell viability in % were noted. 
 
2.4.5 Preparation of cells for cryopreservation 
Culture flask was observed under phase contrast microscope to ensure live and 
healthy cells. After removing the media, the flask was washed twice with 37˚C PBS . 
An appropriate amount of trypsin was added depending on the size of the plate (Table 
2.2) and incubated at 37˚C for 3 min. The flask was observed under the microscope 
to ensure all the cells have dislodged. Using 5 ml of PM the flask was washed, all the 
cells collected in a 15 ml tube for centrifugation. Centrifugation was performed at 115 






media was added and triturated for single cell suspension. The cells were counted 
using Automated cell counter (Countess II), as previously described. Freezing media 
(2.1.6) was added accordingly to obtain 1x10^6 /ml concentration. The cell suspension 
was then quickly transferred to cryovials and placed in Mr.Frosty (Freezing container, 
Thermo Scientific™) and placed in -80˚C overnight. The next day the vials were 
transferred to liquid nitrogen tank. 
      
2.4.6 RNA isolation  
 Following removal of culture media, cells were lysed with 500 µl of Tripure (cat 
# 11667157001, Sigma-Aldrich (Pty) Ltd, Missouri, USA) and the lysate removed and 
stored at -20˚C prior to RNA isolation. The Eppendorf tube with lysed cells in Tripure 
was allowed to thaw completely on ice. 100 µl of chloroform (cat # C2432, Sigma-
Aldrich (Pty) Ltd, Missouri, USA) was added to the lysate and mixed by inverting the 
tube for 15 sec and let it stand at RT for 5 min. Thereafter, the sample was centrifuged 
at 13,500 rpm for 15 min at 4˚C which formed 3 distinct layers. The clear supernatant 
was carefully transferred to a new Eppendorf tube prior to the addition of 250 µl of 
Isopropanol (cat # I9516, Sigma-Aldrich (Pty) Ltd, Missouri, USA). The sample was 
centrifuged again at 13,500 rpm for 15 min at 4˚C and the supernatant was discarded. 
The remaining pellet was resuspended in 500 µl of 70% Ethanol and centrifuged at 
7,500 rpm for 7 min at RT. This step was repeated three times. The supernatant was 
discarded and the tube air dried for about 30 min (until ethanol was completely 
evaporated). The pellet was finally eluted with 20 µl of RNA/DNA free water and 
measured for RNA quantity and purity using Nanodrop lite  
 
2.4.7 Measuring RNA using Nanodrop lite (Thermo Scientific™) 
The Nanodrop lite is a compact microvolume spectrophotometer providing 
accurate and reproducible measurements without the need for dilutions. Nanodrop lite 
can be used to measure nucleic acid concentration at 260 nm and purity using 260/280 
ratio. Purified protein can be measured at 280 nm. 
To confirm purity and RNA concentration, the eluted samples were measured using 
the Nanodrop lite (Thermo ScientificTM).  The instrument contact point was cleaned 





blank measurement. After setting blank twice, the contact point was blotted using lint 
free paper, 1 µl of sample was loaded and measured.  The RNA concentration was 
quantified in ng/µl and purity was noted in ratio of 260nm/280nm wavelength. 
 




ng/µl Test 1 (260nm) 
RNA concentration 







KH 1.3 P 425.5 428.1 426.8 1.96 
KH 1.3 Q 389.6 390.6 390.1 1.99 
KH 1.3 PF2 574.9 589.6 582.25 1.94 
KH 1.3 QF2 427.4 436.1 431.75 1.90 
 
2.4.8 cDNA preparation with two different first strand cDNA kits 
All procedures were performed on ice. 
Prior to starting the procedure, a table was prepared with number of samples, 
concentrations of RNA, starting with least concentration of RNA, volume to RNA in µl 
and volume of dH20 to pipette for each sample to obtain final volume of 11µl with equal 
concentration of RNA in each tube. Thermal cycler (Applied biosystems 2720) was 
used to synthesize the first strand cDNA.  
 
 















KH 1.3 P 426.8 10.05 0.95 11 ul 4291.1 
KH 1.3 Q 390.1 11 0 11 ul 4291.1 
KH 1.3 PF 582.25 7.37 3.63 11 ul 4291.1 






2.4.8.1 Details about the instrument 
Applied Biosystems 2720 thermal cycler is a standard PCR equipment with 96 
well reaction plate area. Programable thermal block with heated lid allows to cycle 
through repeated temperatures required with 0.2 ml reaction tubes. Initial optimization 
was done using gradient temperatures. 
 
Note: Two different cDNA synthesis kit were used, results were scrutinized, and the 
suitable kit was chosen for all further tests. 
 
2.4.8.2 Revert Aid First strand cDNA Synthesis kit H minus 
Required samples of template RNA were collected and allowed to thaw on ice. 
Table with the concentrations of RNA was consulted to pipette required amount of 
RNA to separate 200 µl RNAse free tube followed by required amount of dH20. 1 µl of 
Random Hexamers was added and mixed by tapping the bottom of the tube gently. 
The mixture was incubated at 65˚C for 5 min followed by 1 min cooling on ice. 5x 
Reaction buffer (4 µl), Ribolock RNase inhibitor (1 µl), 10 mM dNTP mix (2 µl), and 
Revert Aid (1 µl) were added to each sample, mixed and centrifuged briefly. The tubes 
were then transferred to PCR thermal cycler and was run with the following protocol. 
5 min @ 25˚C → 60 min @ 42˚C → 5 min @ 70˚C. The tubes were then preserved at 
-20˚C for short term, -80˚C for long term or used immediately for PCR reactions. 
 
2.4.8.3 Superscript IV first strand kit 
Using the Superscript IV first strand kit, the template RNA samples were 
collected and allowed to thaw on ice. The concentration table was consulted to pipette 
the required amount of RNA, 50 µM oligo dT and 10 mM dNTP were added to each 
tube and incubated @ 65˚C for 5 min followed by cooling on ice for 1 min. 10x RT 
Buffer 25 mM MgCl2, 0.1 M DTT, RNase out and Superscript III were added to each 
tube. The mixture was then incubated in the PCR thermal cycler (Applied Biosystems, 
2720) at 50˚C for 50 min. 
 
Note: Superscript IV first strand kit was chosen for all further analysis due to the 





2.5 Quantitative Polymerase Chain Reaction 
2.5.1 qPCR Primers 
Initial PCR runs were performed with gradient annealing temperature from 
54.5˚C to 60.5˚C) in order to optimize conditions. 57.5˚C was chosen as the optimal 
temperature as all the primers annealed well and produced a single amplicon fragment 
indicated by uniform melt curve.  





Forward.Primer (5'- 3') TGGTGCTGAGTATGTCGTGGAGT 
Reverse.Primer (3'- 5') AGTCTTCTGAGTGGCAGTGATGG 
MYF5 
Forward.Primer (5'- 3') AATTTGGGGACGAGTTTGTG 
Reverse.Primer (3'- 5') CATGGTGGTGGACTTCCTCT 
MYOD1 
Forward.Primer (5'- 3') TGCACGTCGAGCAATCCAAA 
Reverse.Primer (3'- 5') CCGCTGTAGTCCATCATGCC 
PAX7 
Forward.Primer (5'- 3') CCCCCGCACGGGATT 
Reverse.Primer (3'- 5') TATCTTGTGGCGGATGTGGTTA 
MKI67 (Ki67) 
Forward.Primer (5'- 3') TGACCCTGATGAGAAAGCTCAA 
Reverse.Primer (3'- 5') CCCTGAGCAACACTGTCTTTT 
p21 
Forward.Primer (5'- 3') TCTTGTACCCTTGTGCCTCG 
Reverse.Primer (3'- 5') ATCTGTCATGCTGGTCTGCC 
 
2.5.2 qPCR primer concentration 
Table 2.6 qPCR primer concentration 
Primer Name GC content in % Molecular weight Tm in ˚C 
GAPDH F 52.2 7181.7 59.9 
GAPDH R 52.2 7150.7 58.7 
MYF5 F 45.0 6243.1 53.4 
MYF5 R 55.0 6115.0 56.6 
MYOD1 F 50.0 6095.0 57.6 
MYOD1 R 60.0 6028.9 58.2 
PAX7 F 73.3 4514.0 58.7 
PAX7 R 45.5 6827.5 56.1 
MKI67 F 45.5 6752.5 56.0 
MKI67 R 47.6 6332.2 55.5 
P21 F 55.0 6025.9 57.0 






2.5.3 Reagents used for qPCR 
 qPCR was performed using SYBR Green dye (cat # 4472908, Thermo Fisher 
Scientific, Massachusetts, USA) . It is a commonly used fluorescent dye which binds 
to the double-stranded DNA by intercalating between the DNA bases. The 
fluorescence can be measured at the end of each amplification cycle to determine 
relative and absolute amplification of DNA. 
 
2.5.4 qPCR plating 
 qPCR was similarly performed on the PCR Thermal cycler (Applied biosystems, 
2720). 10 µl of each sample was loaded into each well in triplicate. One set of positive, 
negative and blank controls were used on every plate.  
2.5.5 qPCR running protocol for Applied Biosystems instrument. 
The StepOnePlus™ Real-Time PCR system was used to perform qPCR with 
temperature settings detailed in Table 2.6. This instrument is a 96 well instrument with 
4 colour optical LED recording system connected to a Windows computer. The 
program temperature and time settings used for the qPCR run are described in Table 
2.7. The SYBR green reporter dye was used. 
Table 2.7 qPCR instrument protocol 
Protocol Temp in ˚C Time Parameter 
UDG activation 50 2 Min Hold 
Dual lock 95 2 Min Hold 
Denature 95 15 Sec  
40 Cycles Anneal 57.5 15 Sec 







Figure 2.4 Representative qPCR reaction plot. X-axis representing the number of 
cycles and the fluorescence. The Y-axis represents the product amplification from the 
reaction minus the baseline. 
 
The represented qPCR plot shows the number of cycles (X-axis) and fluorescence of 
the Sybr Green reporter dye minus the baseline (ΔRn). The Ct value is calculated from 
the plot and represents the target threshold (red) which is the number of cycles 
necessary for the fluorescent signal generated to rise above the background levels. 
The Ct value of the qPCR amplification graph is inversely proportional to the number 
of copies of the mRNA transcripts. The amount of doubling or amplification needed for 
the fluorescence signal to raise above the background noise represents the amount 
of mRNA transcript present in the sample. A lower Ct indicates higher mRNA 
transcripts as it does not need many amplification cycles. The trace on the farthest 
right on the plot would have a lower number of the mRNA transcript because its target 
threshold (red) is higher indicating an increased number of cycles required for the 
fluorescent signal to rise above background 
2.5.6 qPCR data analysis. 
 qPCR data was analyzed using the delta delta Ct method (ΔΔct) to quantify fold 
change between control and test sample. The mean cycle threshold (Ct) of the 
triplicate, normalized against housekeeping gene GAPDH, as well as normalization 





formula to normalize against housekeeping gene (control) and normalizing against 
control sample gene used:  
= mean of test Ct – mean of control Ct (ΔCt),  
= ΔCt of test gene – ΔCt of control gene (ΔΔct).  
= 2^-(ΔΔct)  
= Fold change 
 
2.6 Cell cycle measurements with flow cytometry 
2.6.1 Preparing samples for cell cycle analysis. 
The BD cell cycle analysis kit was used (cat # BD/340242, Becton Dickinson, 
New Jersey, USA). Post cell culture, cells were trypsinised, centrifuged and counted 
using automated cell counter. Cell concentration was maintained at 1 million cells /ml. 
500 µl of cell cycle buffer was used to wash the cells twice followed by staining with 
Solution A, B and C according to manufacturer’s guidelines. 
Cells were pelleted down to the concentration of 1x106 /ml. 250 µl of solution A 
(trypsin in a spermine tetrahydrochloride detergent buffer) was added and mixed 
gently and incubated for 10 min at RT. 200 µl of solution B (trypsin inhibitor and 
ribonuclease A in citrate-stabilizing buffer with spermine tetrahydrochloride) was 
added to the existing mix and incubated at RT for 10 min after gentle mixing. Finally, 
200 µl of solution C (Propidium Iodide (PI) and spermine tetrahydrochloride in citrate 
stabilizing buffer) was added and incubated for 10 min at 4˚C in the dark. The sample 
was then used for analysis. 
 
2.6.2 Description of instrumentation used for Flow cytometry. 
The BD FACSAria II flow cytometer is a high-speed fixed-alignment benchtop 
cell sorter, equipped with 488 nm, 633 nm and 405 nm solid state lasers for 
fluorochrome excitation, for the simultaneous analysis of up to 9 fluorescent markers 





and BD FACSAria II cytometer functions are performed and controlled by BD 
FACSDiva v8.1 software. 
The cell sorter employs detector arrays with photomultiplier tubes (PMTs) and a 
photodiode detector to detect and amplify signal. An octagon detector array contains 
six PMTs that detect SSC and up to five fluorescence signals excited by the blue laser. 
The trigon arrays contain two PMTs to detect fluorescence signals excited by the red 
and violet lasers, respectively. The FSC signal is detected by the photodiode detector. 
The PMTs convert photons into electrical pulses, which are subsequently processed 
by the electronics system and converted into visual data.  
The flow cytometric acquisition was performed at the Central Analytical Facilities 
(CAF) Fluorescent Imaging Unit, Stellenbosch University.  Cell samples were analyzed 
on the BD FACSAria IIu flow cytometer (BD Biosciences, San Jose, USA) using BD 
FACSDiva™ version 8.1 software for data acquisition and analysis. The light path, 
filters, detectors for the instrument are detailed in Table 2.3. The propidium iodide (PI) 
dye was excited by the 488 nm laser and the fluorescence detected in the 595 long 
pass filter and 610/20 band pass filter. The sample tubes were resuspended by 
vortexing for 5 seconds before acquisition. . For data acquisition, a minimum of 50 000 
gated, singlet events were collected for each sample tube. Data was further analysed 















Table 2.8 Detectors, Parameters and Filters on BD FACSAria IIu 









 SSC SSC n/a 488/10 Linear 
         Blue 488-C 
PE-Texas 
Red 
595 610/20 Log 
488nm         488-B PerCP Cy5.5 655 695/40 Log 
Red 633-B APC-Cy7 755 780/60 Log 








n/a 530/30 Log 
Legend:          
SSC – Side Scatter   
APC – Allophycocyanin  
Log – Logarithmic   
 
2.6.3 Gating strategy for Cell Cycle analysis 
Figure 2.7 (Ungated), 2.8 (Live cell gating) and 2.9 (Gated) illustrates the gating 
strategy employed for cell cycle analysis of PHMs. A forward scatter (FSC) versus side 
scatter (SSC) dot plot distinguished cells from debris. Within the cell gate, singlets 
were gated using the fluorescent channel, PE-Texas Red, to detect PI staining. 
Thereafter, gates were created to identify the various stages of cell cycle, namely 
G0/G1, S-phase and G2/M. To gate live cells separately from debris, proliferative 
control samples were employed as gating controls. To gate different phases of cell 
cycle, a quiescent sample was used as gating control to distinguish sub-populations. 
After bulk gating, the gates were checked and adjusted manually for each sample. All 



















Figure 2.7 Representation of flow 
data before gating 
Figure 2.8 Representation of 
live cell gating 
Figure 2.9 Representation of gated 












3.1 Introduction  
The comparative index was established as a tool to compare primary cells’ rate 
of proliferation. Primary cells are isolated from living donors. As previously discussed, 
conditions prior to tissue harvesting and cell isolation may cause variation in the 
behaviour of primary cells isolated from different individuals even with no experimental 
intervention. Therefore, comparison is essential when cells are harvested from 
multiple donors. Understanding the differences in cell characteristics would help to 
establish a baseline from which further evaluations can be assessed considering 
inherent variability. However, no clearly defined protocols exist to quantify primary 
cells’ characteristic behaviour in vitro. 
 
The eukaryotic cell cycle can be broadly divided into 4 distinct phases namely G1 
(Gap1 phase), S phase (synthesis phase), G2 (Gap2 phase) and M phase (mitosis 
phase) [84]. Division of cells in culture can vary significantly depending on the type of 
cell. In the initial phase of G1, activation of the Cdk complex initiates the accumulation 
of M-cyclin for mitosis [85]. Since the transition from G1 to S phase represents a big 
change in transcription of genes. Therefore, the total RNA isolated at the 
corresponding timepoint can be used as a marker of the proliferative capacity of the 
cell.  
Therefore, the comparative index was developed using cell cycle progression and total 
RNA quantification. Cell phase was used as a marker whilst the objectively quantifiable 
parameter, total RNA, was used as a comparison. Since large quantities of mRNA for 
downstream applications can be isolated after G1, the “S” phase of the cell cycle was 
targeted as the marker. 
When performing in vitro experiments, during which cells are exposed to treatments 
that affect the cellular function at the genomic and protein level, a key aspect 








 Understanding that cells require generation of mRNA and progression through 
the cell cycle to proliferate, the hypothesis was: estimating the percentage of 
progression of cells from G0/G1 to S phase and quantifying the amount of RNA 
generated during the same period of time, could assist in comparing the rate of 
proliferation of the different PHM clones and establishing comparative index. 
 
3.3 Methodology 
Cell cycle progression is an integral part of any proliferating cell. A proliferating 
human cell with complete cell cycle time of about 24 hours spends roughly 11 hours 
in G1 phase followed by 8 hours of S phase and finally about 5 hours which includes 
G2 and M phase [84]. RNA synthesis varies during different phases.  
 
3.3.1 PHM isolation and culture 
PHMs isolated from skeletal muscle biopsies of two young (21,23 yrs) and 
healthy male subjects were compared: S6 and S9. PHMs were isolated from vastus 
lateralis tissue biopsy of the left thigh. Both samples were isolated separately with the 
same protocol as previously described (Chapter 2.3.2.1). PHMs were allowed to 
migrate off incubated explants of the biopsies for the initial harvesting after 5 days 
depending on the confluency. Incubation was done 3 times for S6, each time replating 
the same explant in a new well, resulting in a stock of PHMs called S6.3, whereas one 





                       
 
The primary stock was frozen down in aliquots at passage 2. For experiments in this 
chapter, 1 aliquot was thawed and cells were plated in a T75 flask with proliferation 
media for expansion. Thereafter, 100,000 cells were plated in 12 individual T25 flasks 
coated with ECL. After about 4 days of culture with media change every 2 days, cells 
reached 70% confluency (~550,000 cells). The PHMs in each individual T25 flask were 
trypsinised, counted (using an automated cell counter) and 500 000 cells were 
replated into a new T25 flask. A 2-hour interval was left between each flask. The cells 
were left for 24 hours from the start of the replating of the first flask, resulting in 12 
flasks where cells were plated for different lengths of time ranging from 2 – 24 hours. 
At the end of 2-24 hours of culture (12 flasks), cells from all flasks were harvested into 
separate tubes (15 ml falcon (Sigma Aldrich)), PHMs were counted using an 
automated cell counter (Thermo Fisher Scientific, USA).  
 
3.3.2 Cell analysis 
Total RNA was isolated from cell lysates of 250,000 cells (measured using an 
automated cell counter) using the Tripure Chloroform-isopropanol method (see 
chapter 2.4.4 for detailed method). The remainder of the cells were used for cell cycle 
analysis. PHMs were stained with PI (see chapter 2.6.1 for detailed method), prior to 
cell cycle analysis which was done using flow cytometry to distinguish different cell 
cycle phases.  
 
Figure 3.1 B Representative image of 
isolated primary cells, 10 days after 
plating. 
Figure 3.1 A Representative image of cell 






3.3.3 Statistics and data representation 
Statistical analysis was done on triplicates comparing all time points and 
included unpaired student’s T-tests and two-way ANOVA where appropriate with 
Bonferroni post-hoc tests (GraphPad Prism 7). 
 
3.4 Results 
Data comparing the percentage of cells in S phase at different timepoints for 
S6.3 are presented in Figure 3.2 and total RNA for S6.3 in Figure 3.3. Similarly, for 
S9.1, data are presented in Figure 3.4 and 3.5 respectively. 
PHMs from clone S6.3 had the peak number of cells in S phase (~23%) and total 
mRNA concentration (8933 ng) at 22 hours. In contrast, S9.1 had far fewer PHMs in 
transition to S phase between 2 and 22 hours (only 14%). Compared to S6.3, the total 
mRNA content was also lower (6418 ng) at 22 hours (p<0.0005 for S phase 
concentration) (p<0.005 for total RNA concentration).  
Trendline analysis of both PHMs indicate that the proportion of cells in the S phase 
follows an exponential increase over time (Fig 3.2, 3.4). The r2 values (adjusted to 4 
decimals) of S phase data for S6.3 and S9.1 were 0.8702 and 0.9472 respectively. 
However, increases in total RNA, fit a linear trend for both (Fig 3.3, 3.5). The r2 value 












































TIME LINE IN HOURS
S phase proportions of S6.3
Figure 3.3 Trend line analysis of S6.3’s 
RNA concentration following 
replating.(n=3, r2 = 0.87) 
 
Figure 3.2 Trend line analysis of S phase 
of S6.3’s PHMs following replating.(n=3, 
r2 = 0.87) 
 













































TIME POINT IN HOURS
















For statistical analysis comparing data of the two PHMs, see table A3.3 (in appendix) 
and Figures 3.6 and 3.7. S phase proportion over the 24-hour period indicated that 
S6.3’s PHMs had a higher number of cells in S phase at almost all the time points 
(04,06,10,12,18,20,22,24) (p <0.0005). Post hoc analysis indicated that, within 
statistically significantly time points, hour 22 was the most significant with p <0.0005. 
Timepoints, hour 18 and 24 had the p value of <0.005 and rest of the early time points 



















































TIME LINE IN HOURS
S Phase proportion of S9.1
Figure 3.4 Trend line analysis of S 
phase of S9.1’s PHMs following 
replating. (n=3, r2 = 0.95) 












































TIME LINE IN HOURS
Total RNA concentration of 
S9.1
Figure 3.5 Trend line analysis of 9.1’s 
RNA concentration following replating. 





















































* =  p < 0 .0 5
* * =  p < 0 .0 0 5
* * *  =  p < 0 .0 0 0 5
Figure 3.6 Comparison of S phase between S6.3 and S9.1 PHMs stained with PI. 





Similar to S phase cells in proportions, total RNA concentrations were consistently 
different between the two PHM clones over time. At the 02, 04, 06, 08, 10, 14, 16, 18, 
20 and the 22-hour timepoints, S6.3’s RNA concentrations were higher than S9.1 with 
p values ranging between p<0.05 to p<0.005. Here, the 18-hour timepoint was the 
most significant with p<0.0005, whereas hour 02, 10, 20, 22 had p value of <0.005 










Not only quantitative analysis but also phenotypic differences between the PHMs were 
evident in actively proliferating cells. PHM clones of S6.3’s appeared smaller in size 
compared to S9.1 even though the cells were of the same passage and culture time. 
While PHMs from S9.1 were larger and had closer interactions with other cells but 
were visibly fewer (see Fig 3.8, 3.9). However, clone S6.3 PHMs despite their smaller 
size, were greater in number. 
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* =  p < 0 .0 5
* * =  p < 0 .0 0 5
* * *  =  p < 0 .0 0 0 5
Figure 3.7 Comparison of total RNA concentration between S6.3 .and S9.1 PHMs. 







3.5 Summary of results 
This study sought to establish a protocol to use as a comparative index for 
primary human myoblasts taken from frozen stocks. Specifically, this study aimed to 
develop a protocol that could be used for quantification of differences in PHMs isolated 
from different donors. 
Cell cycle data for both clones S6.3 and S9.1 illustrated an exponential transition from 
G1 phase to S phase over time. However, when comparing the rate of transition, it 
was evident that S9.1 PHMs were slower to transition compared to S6.3. For the 
majority of timepoints, S6.3’s PHMs had a higher rate of entry into S phase 
RNA concentration is higher when cells progress from G1 to S phase preparing for the 
upcoming translation and synthesis of multiple proteins [86]. Total RNA increased with 
similar linearity reflected by the rate constant in both PHM clones despite the different 
proportions of cells in S phase reflected by the intercepts. Differences in total RNA 
concentrations continued throughout the 24-hour time course for the majority of 
timepoints (10 out of 12), S6.3 PHMs had consistently and significantly higher 
concentrations of total RNA than S9.1.  
Taking the two major findings together, comparison of S phase proportions and total 
RNA suggests that S9.1 PHMs had a slower rate of proliferation compared to S6.3. 
Figure 3.8 20x image of proliferating 
PHMs S6.3 






The time course used to establish these differences was important to differentiate 
clone behaviour.  
 
3.6 Calculating Index  
3.6.1 Method 1 A 
Since the S phase precedes mitosis and the preparation for mitosis requires 
more gene transcription and translation than to maintain cells in Go/G1, it was decided 
to use proportion of cells in S phase at a particular time point within the 24 hr duration 
of culture and the amount of total RNA present at this time to derive an Index. The 
data presented therefore includes comparison of both S phase proportion and total 
RNA at multiple time points by dividing the total RNA (numerator for the equation) by 
the % of cells (denominator for the equation) in S phase at the particular time point. 
Thereafter, the next part of this chapter sought to reduce this abundant information 
into an index. 
The index number or the “comparative index” was calculated as the sum of all the 
calculations made for each time point. Given that in S-phase, mRNA is already being 
translated and therefore, total RNA would be reduced, the index can be interpreted in 
this way: higher index number represents slower rate of cell cycle progression with 
more cells not proceeding with translation, whereas lower index number represents 
faster translation of mRNA into protein and progression in cell cycle, when comparing 
the two clones. 
Sum of all the S phase time points of clone S6.3 was 101.67 and the sum of total RNA 
of all time points was 78602.66 yielding the index number 773.12 
Sum of all the S phase time points of clone S9.1 was 61.01 and the sum of total RNA 









Table 3.2 S phase proportion and total RNA concentration of S6.3 and S9.1 with 
calculation of comparative index using method 1 A for all the time points 
Mean (n=3) S6.3     
Mean 
(n=3)S9.1 
    
Duration 






Total RNA  
Comparative 
index 
(%) (ng)     (%) (ng)   
Time- 
point     
  
Time-
point     
  
(hr)   (Hr)   
02 3.73 4704.00 1261.13 02 1.41 2312.00 1639.71 
04 2.32 5032.00 2168.97 04 1.35 2174.67 1610.87 
06 2.39 5440.00 2276.15 06 1.39 2648.00 1905.04 
08 2.45 5448.00 2223.67 08 1.49 2690.67 1805.82 
10 3.37 6073.33 1802.18 10 1.98 3104.00 1567.68 
12 3.98 5209.33 1308.88 12 2.38 3741.33 1571.99 
14 5.91 6384.00 1080.20 14 4.32 4585.33 1061.42 
16 7.11 7133.33 1003.28 16 5.20 5150.67 990.51 
18 11.08 8006.67 722.62 18 6.03 5524.00 916.09 
20 15.43 8292.00 537.39 20 10.63 6014.67 565.82 
22 22.74 8933.33 392.85 22 11.15 6418.67 575.67 
24 21.16 7946.67 375.55 24 13.68 6674.67 487.91 
        
SUM 101.67 78602.66 773.12 
(Calculated 
CI) 




3.6.2 Method 1 B 
However, viewing the Figures 3.2, 3.4, one can visualize there is no significant 
progression from G0/G1 towards S phase until the timepoint of 12 hours. If the 12-
hour time point is taken as the base time point for starting to calculate the sum (Σ) 12-
hour time point, then the difference between the comparative index calculated for each 
clone was increased from 63.45 to 119.98. In other words, using all time points 
(Method 1A) the index difference was 63, but using method 1 B, the difference was 
119 suggesting better sensitivity. This in terms of physiological context suggests that 
initial 12 hours (for both the PHMs) was required to prepare the cells to start 








Table 3.3 phase proportion and total RNA concentration of S6.3 and S9.1 with 
calculation of comparative index using method 1 B for the time point starting from 12 
hours. 
12 3.98 5209.33 1308.88   12 2.38 3741.33 1571.99 
14 5.91 6384.00 1080.20   14 4.32 4585.33 1061.42 
16 7.11 7133.33 1003.28   16 5.20 5150.67 990.51 
18 11.08 8006.67 722.62   18 6.03 5524.00 916.07 
20 15.43 8292.00 537.39   20 10.63 6014.67 565.82 
22 22.74 8933.33 392.85   22 11.15 6418.67 575.67 
24 21.16 7946.67 375.55   24 13.68 6674.67 487.91 
         
SUM 87.41 51905.33 593.82   53.39 38109.34 713.79 
 
3.6.3 Method 2 A 
The index number or the “comparative index” for method 2 A was calculated by 
calculating the area under the curve using the trapezoidal rule, for the total RNA and 
the % of cells in S phase. The higher index number represents slower rate of cell cycle 
progression whereas lower index number represents faster rate of cell cycle 
progression when comparing 2 clones (see appendix table A3.4 for raw data and table 
A3.5 for calculations). 
 
Area under the curve: using composite trapezoidal rule. 
S phase proportion    of S6.3 = 178.45 
Total RNA concentration  of S6.3 = 144554.65 
Comparative Index => 144554.65/178.45 = 810.1 
 
S phase proportion    of S9.1 = 106.93 
Total RNA concentration  of S9.1 = 93090.69 





The comparative index represents S9.1’s (870.58) rate of progression to S phase is 
slower compared to S6.3 (810.1) 
Using this method, the difference between the two clones appeared narrower, similar 
to method 1A 
 
3.6.4 Method 2 B 
Applying the similar 12 hour time point rule for the area under the curve method 
resulted in a similar result to Method 1 B.  
 
Area under the curve: using composite trapezoidal rule. 
S phase proportion    of S6.3 = 149.68 
Total RNA concentration  of S6.3 = 90654.66 
Comparative Index => 90654.66/149.68 = 605.66 
 
S phase proportion    of S9.1 = 90.72 
Total RNA concentration  of S6.3 = 65802.68 
Comparative Index => 65802.68/90.72    = 725.34 
The comparative index indicates that S9.1’s (725.34) rate of progression to S phase 











3.6.5 Summary of the comparative index values. 
 
Table 3. 1 Summerising the comparative index models. 
 
3.6.5.1 Summary for calculation of Comparative Index 
All the different methods tested here were options for a comparative index of 
the tested samples which also indicated differences between the two clones. Although 
Method 1 A and 2 A were true in mathematical terms, applying it to the physiological 
context is problematic. Two important reasons persuaded us to recommend Method 1 
B and Method 2 B. a) The index values were further apart than 1 A or 2 A, thus possibly 
improving sensitivity in future comparisons of more clones. b) The physiological 
context appeared to be more relevant between clones from the 12-hour time. Hence, 
we propose to use Method 1 B or 2 B for all further calculations of comparative index. 
3.7 Conclusion 
The experiment was able to distinguish the rate of proliferation between clone 
S6.3 and S9.1.  
Rate of proliferation between clones was calculated using two different methods with 
a proposal to use method 1B or 2B for further comparisons. 
Clones S6.3 and 9.1 have similar lag phase, before the exponential shift from G0/G1 
to S phase. 
 
 
Method S 6.3 S 
phase 
Total RNA CI S 9.1 S 
phase 
Total RNA CI Fold  
change 
1A SUM 101.67 78602.66 773.12 SUM 61.01 51038.68 836.56 1:1.08 
2A SUM 178.45 144554.65 810.1 SUM 106.93 93090.69 870.58 1:1.08 
1B SUM 87.41 51905.33 593.82 SUM 53.39 38109.34 713.79 1:1.12 





Chapter 4: Comparison of two quiescence protocols  and development of a 








 Skeletal muscle has a tremendous ability to regenerate when an injury occurs. 
The timeline of skeletal muscle regeneration depends on the type and site of injury. 
The typical regeneration sequence begins within a few hours of injury and is completed 
in about three to four weeks. However, in the case of severe trauma, the time line 
could be longer than four weeks [87]. Initiation of regeneration is complex, but many 
of the responses serve to influence satellite cells [88] in various ways. In severe 
injuries, continued regeneration is dependent on a pool of satellite cells [89]. 
In vivo, in healthy uninjured skeletal muscles, satellite cells reside in a state of 
dormancy (quiescence). Following skeletal muscle injury, satellite cells are activated, 
proliferate and differentiate to aid the regeneration process. Differentiated satellite 
cells donate nuclei during fusion with damaged myofibers. A small portion of the active 
cells return to the G0 state to restore the quiescent cell pool. To best mimic the in vivo 
environment, it is necessary to simulate reversible in vitro quiescence in cultured 
myoblasts.  
“In vitro quiescence” is relatively a new concept [90]. As a result, there are a limited 
number of experimental protocols available. In this chapter, the first aim was to 
determine if in vitro quiescence could be achieved in the same myoblast clones using 
two different methods. Thereafter the aspects of the two different in vitro quiescence 
protocols were used for development of a novel “blended protocol”. 
 
4.1.1 Suspension culture induction of in vitro quiescence. 
 As mentioned in the introduction (chapter 1.2.1), in order for PHMs to proliferate 
in vitro, cells require cell to surface contact for anchoring and cell-to-cell contact for 
signalling. The original publication on in vitro quiescence induction was performed by 
depriving PHMs of these two factors using suspension culture (SuCu) for 48 hours 
[43]. This method showed that reversible cell cycle exit can be achieved using 
suspension culture containing 2% methyl cellulose that both provided a dense semi-
solid medium which deprived the cells from settling to the bottom of the culture well, 
and kept them suspended in the medium. Uniform mixing of the cells with the 





provides necessary cell culture growth factors so that quiescent cells can actually 
remain viable and subsequently re-enter cell cycle. This is the first protocol that will be 
demonstrated here. 
 
4.1.2 KOSR culture induction of in vitro quiescence. 
Other studies have induced quiescence in different cell types [91, 92]. In the 
field of embryonic stem cell biology xeno free media called KOSR has been used [93]. 
Recently, our research group showed that substitution of FBS with KOSR in the culture 
media without suspension and without growth factor supplementation induced 
quiescence in 10 days. That study confirmed that 95.6% of cells were in G0/G1 phase 
after 10 days. That study assessed both Pax7 and MyoD. The current study included 
additional markers including P21, a controller of quiescence, and Myf5, a promoter of 
self-renewal.  
Whilst both protocols have previously been shown to result in effective quiescence 
after the intended periods, each one has its own limitations.  
 
4.2 Pros and cons of the two individual protocols. 
Firstly, SuCu with FBS is a relatively quick protocol nudging PHMs into the 
G0/G1 phase of the cell cycle within 48 hours. However, with SuCu the PHMs cannot 
be visualised using microscopy to assess the morphology while suspended in the 
methyl cellulose. Also, the protocol requires special training to achieve effective 
quiescence. Most importantly, soon after harvesting the cells from the suspension 
media, PHMs tend to become active [43]. 
The KOSR culture method, on the other hand, does not require any special training 
and morphology can be monitored throughout due to PHMs being adhered to a flask. 
The main limitations with this method are that 10 days are required to attain effective 
quiescence and the absence of growth factor supplementation does not effectively 
simulate in vivo conditions, even in the niche where satellite cells are quiescent [94]. 
Therefore, this chapter aimed to combine the two protocols in a novel “blended 





improved quiescence, with reference to lower expression of cell proliferation gene and 
myogenic regulatory factors,  could be achieved in a briefer time span than using 
KOSR alone. 
4.3 Hypothesis 
Considering that both SuCu and KOSR treatment results in quiescence, it was 
hypothesised that replacing the FBS component of the previously used SuCu method 
with KOSR, quiescence would be achieved within a relatively short period of time. 
 
4.4 Brief Methodology 
PHMs isolated from skeletal muscle biopsies of three young and healthy male 
subjects were harvested and assessed for myotube formation as previously described 
(Chapter 2.3.2). Two different types of SuCu media were prepared with either FBS or 
KOSR (chapter 2.1.4) After 48 hours of SuCu, PHMs were harvested using 1xPBS 
and 250,000 PHMs were used for total RNA isolation using the phenol-chloroform 
method (chapter 2.4.4) for qPCR analysis. qPCR was performed using Sybr Green 
dye (Applied biosystems StepOnePlusTM Thermofisher) to assess the gene 
expression on selected markers:  ki67, myf5, MyoD and p21 (see chapter 2.5 for 
detailed methods). For cell cycle analysis, first 50,000 events were assessed. 
Data reduction and analysis: Cell cycle data are presented as a percentage in a 










Firstly, it was necessary to validate 
induction of cellular quiescence using the 10 
day KOSR protocol. To this end, actively 
proliferating PHMs were harvested and 
compared to the KOSR method using flow 
cytometry and qPCR. Cell cycle analysis 
indicated that a large proportion (93.13%) of 
cells were arrested in G0/G1 state compared 
to that seen in the proliferating cells (Fig.4.1) 





Due to activation of PHMs with harvesting from SuCu, cell cycle was not assessed in 
SuCu method. In contrast mRNA has a longer half-life thus able to reflect the pre-
harvest conditions.  
qPCR analysis on PHMs exposed to either KOSR or SuCu conditions was used to 
compare the gene expression of ki67, myf5, MyoD and p21. There were no differences 
in the expression of ki67, MyoD and p21, however myf5 expression was higher in cells 
cultured in KOSR (Fig 4.2).  
Figure 4.1 Comparison of  PHMs 
(CloneKH3) proliferating vs in 
quiescence using flow cytometry to 
assess proportion of cells in  G1, S and 
G2 phases of the cell cycle. The 10 days 
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Figure 4.2 Expression of transcription factors influencing proliferation including 
myogenic regulatory factors in PHMs induced into in vitro quiescence with suspension 
culture (SuCu) and knock-out serum replacement (KOSR). Following induction of 
quiescence using 48 hour treatment in SuCu or 10 days in KOSR media, cells were 
harvested and gene expression quantified from isolated RNA. Results represent 
means ± SEM (n=3) 
 
 
For the third condition, the expression of ki67, myf5, MyoD and p21 were quantified in 
PHMs treated with SuCu supplemented with either FBS or KOSR (Figure 4.3). 
Expression of ki67, myf5 and MyoD were significantly lower in PHMs treated in SuCu 
KOSR. However, there was no statistical difference in P21 gene expression, although 













To compare all three protocols (SuCu FBS, SuCu KOSR and 10d KOSR), the data 
from Figure 4.2 and 4.3 were merged (Fig 4.4) and suitable statistical test was 
performed (see legend of Fig 4.4). The novel blended protocol of replacing FBS with 
KOSR in SuCu (SuCu KOSR), resulted in the lowest relative expression levels of ki67, 
myf5 and MyoD among all three protocols. ki67 of SuCu KOSR was significantly lower 
than SuCu FBS (although not different from KOSR alone). myf5 and MyoD were 
significantly lower compared to both SuCu FBS and KOSR. p21 on the other hand was 
significantly upregulated in SuCu KOSR compared to SuCu FBS and no significant 







Figure 4.3 Expression of transcription factors influencing proliferation including 
myogenic regulatory factors in PHMs induced into in vitro quiescence with SuCu 
supplemented with FBS (SuCu FBS) or  knock-out serum replacement ( SuCu KOSR). 
Following induction of quiescence using 48 hour treatment in SuCu, cells were 
harvested and gene expression quantified from isolated RNA. Results represent 
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The 10 day KOSR protocol successfully altered the proportion of cells in the 
active phases of the cell cycle. When comparing the two individual protocols (SuCu 
FBS & 10 day KOSR), higher gene expression of myf5 was observed in 10 day KOSR. 
This may be indicating somewhat greater affinity towards myogenic lineage in 10 day 
KOSR compared to SuCu.  
Expression of ki67 and MyoD were below 1-fold indicating that both protocols are 
effective in reducing factors that promote proliferation. Quiescence was achieved in a 
synchronous fashion since very high proportion of PHMs were in G0/G1 phase. The 
presence of methyl cellulose in the harvested cells from SuCu prevented cell cycle 
analysis in the SuCu sample. 
Since p21 had an exceptionally high fold-change, it can be concluded that a major 
mechanism by which both protocols achieved synchronous quiescence in vitro was by 
inhibition of cell cycle.  
The lowest expression of pro-proliferative markers and myogenic regulatory factors 
was in the blended protocol SuCu KOSR. This supports the hypothesis that substitution 
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*  =  p < 0 .0 5
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Figure 4.4 Comparison of KOSR, SuCu FBS, SuCu KOSR protocols in KH3. 








The 10 day KOSR protocol resulted in high proportion of cells in the G0/G1 phase 
thereby inducing cellular quiescence. 
The development of the SuCu KOSR method resulted in reduced ki67 expression 
indicating an improved reversal of proliferation was achieved using this blended 


















5.1 Introduction to Fibroblast Growth Factors (FGF 2 & 6). 
The various FGFs are vital members of the growth factor super family which 
aid in embryonic and foetal development [95]. In humans, both during the postnatal 
growth phase and in adult tissue regeneration, the number of satellite cells play equally 
important roles [26]. FGFs are active in angiogenesis and promote cell proliferation 
and differentiation in a variety of cell types and are therefore critically important for 
typical multicellular development. Twenty-two different FGFs have been identified in 
the human genome [45]. FGFs bind to four receptors (FGFR1-FGFR4) with 
downstream signalling leading to altered gene expression. 
Basic FGF or FGF-β is encoded by the FGF2 gene and hence also called FGF2. FGF2 
is an 18 kDa 155 amino acid polypeptide which can bind to different FGF receptors for 
associated function [96]. It has been shown to be particularly highly expressed during 
embryonic development contributing to a number of developmental functions. 
Therefore, FGF2 is a common additive in human embryonic stem cell culture media 
as a mitogen as well as to maintain stem cells in a proliferative state [53, 97]. Tissue 
breakdown in the adult is frequently followed by embryonic + foetal programme for 
healing [98]. This ability of FGF2 to stimulate proliferation has resulted in clinical trials 
where it has not only been used in skeletal muscle but also in different tissue in relation 
to regeneration [99]. In myogenesis, FGF2 has been combined with different 
treatments to achieve effective regeneration resulting in clinical trials [100, 101]. 
Activation of the satellite cells using FGF6 is still biased [70, 102]. The current study 
used the application of both FGF2 and 6 to investigate effects on activation and 
subsequent proliferation of activated PHMs.  
FGF6 and its primary function are less well understood compared to FGF2. FGF6 
mouse homolog is found to be expressed predominantly in the myogenic lineage [103] 
and is suggested to be associated with the early stage of regeneration. This was 
investigated on satellite cells with contradictory evidence regarding FGF6-induced 






5.1.1 Fibroblast Growth Factor 2 and 6 in adult wound healing context of 
myogenesis. 
Due to the potential role that FGF6 has in cell activation and the involvement of 
FGF2 in proliferation, utilizing only one type of FGF might not be enough to optimally 
improve the regeneration process. Up to now, studies use FGF2 to promote 
proliferation of active cells, but have not specifically used any other agent to activate 
the quiescent cells. This may be because agents suspected to improve proliferation 
are added to cells that are already proliferating. 
Experiments in vitro have used sequential exposure to FGF2, 9, 18 to aid 
chondrogenic differentiation of hMSCs [99]. 
Applying FGF6 to potentially activate quiescent myoblasts, followed by FGF2 to 
promote proliferation could be an attractive means of expanding PHMs in culture. 
However, the timing of the treatment may hold the key to initiate the particular 
myogenic events at the right time. 
 
5.2 Hypothesis 
Given the current understanding of the FGFs, it was hypothesized that: FGF6 
could be used to initiate the activation process of the quiescent PHMs and FGF2 could 
enhance the proliferation of activated PHMs.  
 
5.3 Aims 
Given the current trend of FGF2 use in pre-clinical and clinical trials [55, 104], 
the first aim was to assess if FGF2 alone can activate the quiescent cells. The second 
aim was to determine if FGF6, not currently used, could activate the quiescent cells. 
Given the hypothesis that FGF6 is involved in activation and FGF2 in proliferation, the 
third aim was to test this sequentially and to compare this in the inverse order. Since 
data is already more available in the literature on FGF2, it was also decided to try the 
two FGF treatments in the reverse order, even though the hypothesis was that FGF6 
activation followed by FGF2 for proliferation. This could assist in understanding the 






Table 5. 1 Illestration of the proposed treatements with concentration and duration. 
 Treatment 1 Treatment 2 Treatment 3 Treatment 4 
Treatments FGF6 FGF2 FGF6 =>FGF2 FGF2 =>FGF6 
Concentration 10 ng/ml 10 ng/ml 10 ng/ml =>10 
ng/ml 
10 ng/ml =>10 
ng/ml 
Duration 24 hours 48 hours 24 => 48 hours 48 =>24 hours 
 
 
Recognition of the ideal protocol for inducing quiescence for FGF experiments:  
The blended protocol was better at inducing quiescence among the methods tested. 
However, the blended protocol still is limited by the inability to visualize cells during 
culture. Secondly, the treatments to be investigated may not have easy access to all 
the myoblasts in the viscus methyl cellulose solution. It was therefore decided that the 
10 day KOSR method was used as the standard method to induce quiescence for the 
remainder of the thesis.  
 
5.4 Experiment 
 The experimental design used three different PHM cell populations isolated 
from healthy donors. Since little is known regarding the myogenic response of PHMs 
to FGF6, a pilot study was done using 2.5, 5, 7.5, 10, 15 and 20 ng/ml to assess cell 
cycle proportions. Among these, two different doses of 5 ng/ml and 10 ng/ml were 
selected for further testing because cell death was observed at the low doses 
(according to live cell gating) and the higher doses did not appear to have any greater 
effect on cell cycle proportions than 10 ng/ml. After assessing RNA yield, 10 ng/ml 
was selected as the optimal treatment dosage, because 5 ng/ml resulted in lower RNA 
yield. FGF2 dosage was kept constant at 10 ng/ml in line with previous studies 
(Appendix Table A5.3 and A5.4)  
Quiescence was induced in multiple clones of PHMs using the 10 day KOSR method 





anticipated effect. Since FGF6 was a potential activation factor, a 24-hour treatment 
period was selected while the pro-proliferative FGF2 was administered to cells for 48 
hours. For the sequential treatments, FGF6 was administered for 24 hours followed 
by FGF2 treatment for 48 hours and vice versa.  
Analysis included flow cytometry for cell cycle analysis and qPCR gene expression of 
ki67, myf5, MyoD and p21. For details of the methods, reagents, primers and 
equipment see chapter 2.5. 
Three different PHM clones isolated from three healthy individuals were statistically 
analysed using Graphphad Prism 7. Results are presented first as n=3 from each 
individual, thereafter those 3 data were averaged, and a statistical average was 
performed for PHMs from the three donor subjects (n=3). 
 
5.5 Results 
The results will be presented first on Flow cytometry for Cell cycle analysis 
followed by qPCR for gene expression.  
Data reduction and analysis: Cell cycle data are presented as a proportion in a specific 
phase (%). qPCR data are presented as fold change relative to quiescent sample 
(n=3). 
 
5.5.1 Flow cytometry  
5.5.1.1 Cell cycle analysis of multiple PHM clones with FGF2 treatment. 
Quiescent PHMs of three different individuals were treated with FGF2 10 ng/ml 
for 48 hours. Quiescent cells and FGF2 treated from each donor were compared. 
Subject S6.3 did not show changes in cell proportions in any of the cell cycle phases 
following treatment, whereas PHMs from KH3 had decrease in the proportion of cells 
in the S phase only following treatment. The proportion of PHMs in the G0/G1 phase 
from KH1 was significantly decreased and G2 phase significantly increased, with no 
change in S phase. Due to these inconsistent results, the individual mean and SEM 










5.5.1.2 Cell cycle analysis of multiple PHM clones with FGF6 treatment 
Next, quiescent PHM clones of the same three different individuals (S6.3, KH3 
and KH1) were treated with FGF6 (10 ng/ml) for 24 hours. 
Significant decreases in the proportions of cells in G0/G1 phase and significant 
increases in S phase were observed in cells from  all donors (Figure 5.1 A, B, C).  
Figure 5.1 Cell cycle analysis of S6.3(A), KH3(B), KH1(C) PHMs, 
comparision of quiescence vs quiescence with FGF2 (QF2) treatment. 
PHMs were harvested and cell cycle analysis performed using PI stain. 
Results represent means ± SEM (n=3) 
 





A significant decrease in G2 phase was also noted in subjects S6.3 and KH3. These 
data are more consistent compared to the responses of FGF2. 
 
5.5.1.3 Cell cycle analysis of multiple PHM clones with sequential treatment of 
FGF6 followed by FGF2. 
Comparison of quiescent PHMs with those treated with single FGF6 or 
sequential treatment of FGF6 and 2 is shown in Figure 5.3. Compared to quiescent 
cells of donor S6.3, PHMs had lower G0/G1 and G2 phase proportions and a higher 
proportion in the S phase following treatment with FGF6 alone (Fig 5.3). Sequential 
treatment with FGF6 followed by FGF2 yielded the same results as FGF6 alone. In 
the S phase, both FGF6 and the combination treatment showed a significant increase 
in the proportion of cells compared to quiescence alone although the sequential 
treatment was less significant. 
Figure 5.2  Cell cycle analysis of S6.3(A), KH3(B), KH1(C) PHMs, comparision of 
quiescence vs quiescence with FGF6 (QF6) treatment. PHMs were harvested and cell 
cycle analysis performed using PI stain. Results represent means ± SEM (n=3) 













Similarly, for clones of KH3 (Fig 5.4), compared to quiescent cells, PHMs had a lower 
G0/G1 phase proportion and was significantly increased in the S phase following 
treatment with FGF6 alone and sequential treatment.  In contrast to S6.3, however, 
sequential treatment with FGF6 and 2 were different from each other in the G0/G1 
Figure 5.3 Cell cycle analysis of S6.3. Comparision of quiescence vs quiescence 
with FGF6 (QF6) vs quiescence with FGF6 followed by FGF2 (QF62) treatment. 
PHMs were harvested and cell cycle analysis performed using PI stain. Results 










































*  =  p < 0 .0 5
* * * *  =  p < 0 .0 0 0 0 5
Figure 5.4 Cell cycle analysis of KH1. Comparision of quiescence vs quiescence with 
FGF6 (QF6) vs quiescence with FGF6 followed by FGF2 (QF62) treatment. PHMs 
were harvested and cell cycle analysis performed using PI stain. Results represent 











































*  =  p < 0 .0 5
* * * *  =  p < 0 .0 0 0 0 5





phase compared to FGF6 alone (p<0.05). There was no significant effect in the G2 
phase following either FGF6 treatment alone or sequential treatment (despite the 
significant difference when comparing only quiescence vs FGF6 Fig 5.2). 
Cells from the KH1 clones, (Fig 5.5), when compared to quiescent cells responded 
similarly to the KH3 interventions. PHMs had a lower G0/G1 phase proportion and 
increases in the S phase following treatment with FGF6 alone and sequential 
treatment (p<0.0005). In contrast to clone S6.3 however, sequential treatment with 
FGF6 and 2 resulted in significantly higher proportion of cells in the G1 phase 
compared to FGF6 alone (p<0.0005). Similarly, to clone KH3, there was no significant 
effect on the G2 phase following treatment with FGF6 alone and sequential treatment.  
 
5.5.1.4 Cell cycle analysis of multiple PHMs with sequential treatment of FGF2 
and FGF6. 
PHMs from S6.3 treated with FGF2 alone showed no change in the proportion 
of cells in the G0/G1 and S phases compared to quiescent cells. There was however, 










































* * *  =  p < 0 .0 0 0 5
* * * *  =  p < 0 .0 0 0 0 5
K H 1  q  v s  q + F G F 6  v s  q + F G F 6 + F G F 2 .
Figure 5.5 Cell cycle analysis of KH3. Comparision of quiescence vs quiescence 
with FGF6 (QF6) vs quiescence with FGF6 followed by FGF2 (QF62) treatment. 
PHMs were harvested and cell cycle analysis performed using PI stain. Results 






Sequential treatment with FGF2 first and then FGF6, resulted in a decrease of 
cell proportions in the G0/G1 phase and an increase in the G2 phase proportions 
compared to quiescent cells. This increase is somewhat more significant than that in 
PHMs treated with FGF2 alone (p<0.005) but only when compared to quiescence and 










PHMs from KH3 (Fig 5.7) responded to FGF2 treatment alone by decreasing the 
proportion of PHMs in the G1 phase and increasing PHMs in the G2 phase, compared 
to quiescent cells (p<0.0005 G1, p<0.005 G2). Sequential treatment with FGF2 and 
then FGF6, compared to quiescent cells, resulted in a decrease in cells in the G1 phase 
and an increase in the both S and G2 phase proportions (p<0.00005 G1, p<0.05 S, 
p<0.0005 G2). Sequential treatment resulted in a significantly lower proportion of cells 









































*  =  p < 0 .0 5
* *  =  p < 0 .0 0 5
* * *  =  p < 0 .0 0 0 5
* * * *  =  p < 0 .0 0 0 0 5
Figure 5.6 Cell cycle analysis of S6.3. Comparision of quiescence vs quiescence with 
FGF2 (QF2) vs quiescence with FGF2 followed by FGF6 (QF26) treatment. PHMs 
were harvested and cell cycle analysis performed using PI stain. Results represent 















Essentially, when treated with FGF2 alone or with sequential treatment with FGF2 and 
FGF6, PHMs from KH1 (Fig 5.8) demonstrated similar changes to those found for 
KH3, although the levels of significance were slightly less. Compared to quiescent 
cells, the significant decrease for G1 phase was subsequently increased in the G2 
phase. However, there were no differences for the S phase even for sequential 















































*  =  p < 0 .0 5
* *  =  p < 0 .0 0 5
* * *  =  p < 0 .0 0 0 5
* * * *  =  p < 0 .0 0 0 0 5
Figure 5.7 Cell cycle analysis of KH1. Comparision of quiescence vs 
quiescence with FGF2 (QF2) vs quiescence with FGF2 followed by FGF6 
(QF26) treatment. PHMs were harvested and cell cycle analysis 








































*  =  p < 0 .0 5
* *  =  p < 0 .0 0 5
* * *  =  p < 0 .0 0 0 5
Figure 5.8 Cell cycle analysis of KH3. Comparision of quiescence vs quiescence with 
FGF2 (QF2) vs quiescence with FGF2 followed by FGF6 (QF26) treatment. PHMs 
were harvested and cell cycle analysis performed using PI stain. Results represent 






5.5.2 Gene expression. 
Four markers were selected for qPCR analysis to address proliferation (ki67) 
myogenic regulation (myf5, MyoD) and cell cycle regulation (p21) in response to FGF6 
or FGF2 treatments performed individually and in succession. Figure 5.9 to 5.16 are 
presented in such a way that the responses of the two different clones can be clearly 
seen. qPCR data is analysed using Δ ΔCT method.  
Note: Towards the end of this chapter, in the summary section, a brief overview table 
and summary are provided with statistical significance of each treatment for easier 
understanding. 
 
5.5.2.1 Comparison of ki67 expression with individual treatment of FGF6 and 
FGF2. 
 Treatment with FGF6 resulted in significant upregulation of the expression of 
ki67 in PHMs of subjects KH3 and KH1 whereas the smaller increase in S6.3 was not 





Figure 5.9 Expression of transcription factor ki67 in PHMs, S6.3(A), KH3(B), KH1(C) 
induced into in vitro quiescence with knock-out serum replacement (KOSR). 
Following induction of quiescence, FGF6 tretment was used for 48 hrs. Cells were 
harvested and gene expression quantified from isolated RNA. Results represent 





In contrast, treatment with FGF2 did not alter ki67 expression compared to quiescent 
cells. 
 
5.5.2.2 Comparison of p21 expression with individual treatment of FGF6 or 
FGF2. 
Treatment with FGF6 resulted in a significant downregulation in p21 expression 
in PHMs from KH3 only (p<0.05), compared to quiescent cells. This result was the 
mirror image of the ki67 gene upregulation for KH3, but this was not the case for PHMs 
from KH1. S6.3 was downregulated however, not statistically significant with p value 




Figure 5.10 Expression of transcription factor ki67 in PHMs, S6.3(A), KH3(B), KH1(C) 
induced into in vitro quiescence with knock-out serum replacement (KOSR). Following 
induction of quiescence, FGF2 tretment was used for 48 hrs. Cells were harvested and gene 
expression quantified from isolated RNA. Results represent means ± SEM (n=3) 
Figure 5.11 Expression of transcription factor p21 in PHMs, S6.3(A), KH3(B), KH1(C) 
induced into in vitro quiescence with knock-out serum replacement (KOSR). Following 
induction of quiescence, FGF6 tretment was used for 48 hrs. Cells were harvested and 





Treatment with FGF2 resulted in downregulation of p21 in PHMs from S6.3 and KH3 
(p<0.05). 
 
5.5.2.3 Comparison of myf5 expression with individual treatment of FGF6 or 
FGF2.  
 Treatment with FGF6 resulted in significant upregulation of myf5 in S6.3 and 
KH1 PHMs (p<0.05) compared to quiescent cells, but this did not reach significance 
in KH3  
 Treatment with FGF2, resulted in upregulation in clone S6.3 only (p<0.05). 
 
Figure 5.13 Expression of transcription factor myf5 in PHMs, S6.3(A), KH3(B), 
KH1(C) induced into in vitro quiescence with knock-out serum replacement 
(KOSR). Following induction of quiescence, FGF6 tretment was used for 48 hrs. 
Cells were harvested and gene expression quantified from isolated RNA. Results 
represent means ± SEM (n=3) 
Figure 5.12 Expression of transcription factor p21 in PHMs, S6.3(A), KH3(B), KH1(C) 
induced into in vitro quiescence with knock-out serum replacement (KOSR). Following 
induction of quiescence, FGF2 tretment was used for 48 hrs. Cells were harvested and 








5.5.2.4 Comparison of MyoD expression with individual treatment of FGF6 or 
FGF2. 
Treatment of FGF6 and FGF2 in all PHMs did not result in any significant 
changes in MyoD expression, compared to quiescent cells, except for upregulation in 
response to FGF6 in KH3 (p<0.05). 
 
Figure 5.15 Expression of transcription factor MyoD in PHMs, S6.3(A), KH3(B), KH1(C) 
induced into in vitro quiescence with knock-out serum replacement (KOSR). Following 
induction of quiescence, FGF6 tretment was used for 48 hrs. Cells were harvested and 
gene expression quantified from isolated RNA. Results represent means ± SEM (n=3) 
Figure 5.14 Expression of transcription factor myf5 in PHMs, S6.3(A), KH3(B), 
KH1(C) induced into in vitro quiescence with knock-out serum replacement (KOSR). 
Following induction of quiescence, FGF2 tretment was used for 48 hrs. Cells were 
harvested and gene expression quantified from isolated RNA. Results represent 





Treatment with FGF2, resulted in no significant upregulation of MyoD in any of the 
PHMs. 
 
5.5.2.5 Gene expression of multiple selected markers with FGF6 treatment 
compared to sequential treatment of FGF6 followed by FGF2.  
 Next, we compared individual treatments to sequential treatment of FGF6 
followed by FGF2. Figures 5.17 to 5.22 are presented so that the responses of each 
clone are visualised at one time, to facilitate visual comparison between the markers. 
In S6.3 PHMs, sequential treatment of FGF6 followed by FGF2 resulted in lower 
expression of ki67 and myf5, compared to individual treatment of FGF6 where there 
was significant upregulation. The expression levels of ki67 and myf5 following 
sequential treatment was similar to that of quiescent cells, however MyoD was 
significantly upregulated compared to both quiescent cells and those treated with 
FGF6 alone (p<0.00005). The sequential treatment resulted in equivalent p21 
expression levels to that of quiescent cells.  
Figure 5.16 Expression of transcription factor MyoD in PHMs, S6.3(A), KH3(B), KH1(C) 
induced into in vitro quiescence with knock-out serum replacement (KOSR). Following 
induction of quiescence, FGF2 tretment was used for 48 hrs. Cells were harvested and 














Similar to clone S6.3, in KH3 PHMs, ki67 and myf5 expressions for sequential 
treatments were lower than the FGF6 treatment alone. However, there was no 
significant effect of sequential treatment on MyoD or p21 expression following 










































Q u ie s c e n c e
Q F 6
Q F 62
*  =  p < 0 .0 5
* *  =  p < 0 .0 0 5
* * *  =  p < 0 .0 0 0 5
* * * *  =  p < 0 .0 0 0 0 5
Figure 5.17 Expression of transcription factors influencing proliferation including 
myogenic regulatory factors in PHM S6.3, induced into in vitro quiescence knock-out 
serum replacement (KOSR). Following induction of quiescence, using 24 hrs treatment 
of FGF6 followed by 48 hrs of FGF2 in KOSR media, cells were harvested and gene 





































Q u ie s c e n c e
Q F 6
Q F 62
* *  =  p < 0 .0 0 5
* * * *  =  p < 0 .0 0 0 0 5
Figure 5.18 qPCR Expression of transcription factors influencing proliferation including 
myogenic regulatory factors in PHM KH1, induced into in vitro quiescence knock-out serum 
replacement (KOSR). Following induction of quiescence, using 24 hrs treatment of FGF6 
followed by 48 hrs of FGF2 in KOSR media, cells were harvested and gene expression 





Similar to clone S6.3 and KH3, in clone KH1, ki67 and myf5 expressions were lower 
than the FGF6 treatment alone. Similar to S6.3 but in contrast to KH3 however, MyoD 
expression was higher following sequential treatment. p21 gene expression was lower 
following sequential treatment compared to both quiescent cells and those treated with 














































Q u ie s c e n c e
Q F 6
Q F 62
*  =  p < 0 .0 5
* *  =  p < 0 .0 0 5
* * *  =  p < 0 .0 0 0 5
* * * *  =  p < 0 .0 0 0 0 5
Figure 5.19 Expression of transcription factors influencing proliferation including 
myogenic regulatory factors in PHM KH3, induced into in vitro quiescence knock-
out serum replacement (KOSR). Following induction of quiescence, using 24 hrs 
treatment of FGF6 followed by 48 hrs of FGF2 in KOSR media, cells were 
harvested and gene expression quantified from isolated RNA. Results represent 






5.5.2.6 Gene expression of multiple skeletal markers with individual FGF2 
compound to sequential treatment FGF2 followed by FGF6  
Sequential treatment of FGF2 followed by FGF6 did not result in any significant 
changes in ki67, myf5 and p21 expression compared to both quiescent cells and those 
treated with FGF2 alone. However, sequential treatment significantly upregulated 
MyoD expression compared to FGF2 treatment alone and quiescent cells (numbers 








5.5.2.7 Comparison of multiple gene expression with individual and sequential 
treatment of FGF2 followed by FGF6  
Similarly, to clone S6.3, in KH3 PHMs, sequential treatment did not have an 
effect on ki67 and myf5 expression with respect to quiescent cells and those treated 
with FGF2 individually. MyoD expression was again upregulated with sequential 
treatment and was significantly higher than quiescent cells and cells treated with FGF2 
alone (p<0.0005). In contrast to clone S6.3, sequential treatment resulted in lower 



































Q u ie s c e n c e
Q F 2
Q F 26
*  =  p < 0 .0 5
* *  =  p < 0 .0 0 5
* * *  =  p < 0 .0 0 0 5
* * * *  =  p < 0 .0 0 0 0 5
Q u ie s c e n c e  v s  Q F 2  v s  Q F 2 + 6
Figure 5.20 Expression of transcription factors influencing proliferation including 
myogenic regulatory factors in PHM S6.3, induced into in vitro quiescence knock-
out serum replacement (KOSR). Following induction of quiescence, using 48 hrs 
treatment of FGF2 followed by 24 hrs of FGF6 in KOSR media, cells were harvested 















5.5.2.8 Comparison of multiple gene expression with individual and sequential 
treatment of FGF2 followed by FGF6  
In KH1 PHMs, sequential treatment of FGF2 followed by FGF6 upregulated 
ki67, myf5 and MyoD expression compared to quiescent cells (p<0.0005 ki67, myf5 
and MyoD). Similar to KH3 PHMs, p21 expression was reduced following sequential 







































Q u ie s c e n c e
Q F 2
Q F 26
* * *  =  p < 0 .0 0 0 5
* * * *  =  p < 0 .0 0 0 0 5
Figure 5.21 Expression of transcription factors influencing proliferation including 
myogenic regulatory factors in PHM KH3, induced into in vitro quiescence knock-out 
serum replacement (KOSR). Following induction of quiescence, using 48 hrs 
treatment of FGF2 followed by 24 hrs of FGF6 in KOSR media, cells were harvested 







5.6 Summary  
Table 5.1 Gene expression of 2 cell cycle markers in response to FGF2 or FGF6 in 
relation each other,  
FGF6 treatment   
 S6.3 KH3 KH1 
ki67 ↑ns              (p=0.068) ↑ *                 (p=0.01) ↑ ***         (p=0.0003) 
p21 ↓ns              (p=0.066) ↓*                 (p=0.02) ~ns           (p=0.44) 
 
FGF2 treatment   
 S6.3 KH3 KH1 
ki67 ↑ns               (p=0.13) ~ns               (p=0.56) ~ns              (p=0.27) 











































Q u ie s c e n c e
Q F 2
Q F 26
*  =  p < 0 .0 5
* *  =  p < 0 .0 0 5
* * *  =  p < 0 .0 0 0 5
* * * *  =  p < 0 .0 0 0 0 5
Figure 5.22 Expression of transcription factors influencing proliferation including myogenic 
regulatory factors in PHM KH1, induced into in vitro quiescence knock-out serum 
replacement (KOSR). Following induction of quiescence, using 48 hrs treatment of FGF2 
followed by 24 hrs of FGF6 in KOSR media, cells were harvested and gene expression 






Table 5.2 Gene expression of 2 markers related to myogenesis in response to FGF2 
or FGF6 in relation each other,  
FGF6 treatment   
 S6.3 KH3 KH1 
myf5 ↑*                   (p=0.01) ns                 (p=0.11) ↑*             (p=0.01) 
MyoD ↓ns               (p=0.11) ↑*                 (p=0.03) ↑ns           (p=0.08) 
 
FGF2 treatment   
 S6.3 KH3 KH1 
myf5 ↑*                (p=0.02) ↑ns              (p=0.20) ~ns              (p=0.41) 
MyoD ~ns               (p=0.24) ↑ns               (p=0.17) ↑ns            (p=0.058) 
Legend: ↑ = Significant upregulation or trend towards significant upregulation  
    ↓ = Significant downregulation or trend towards significant downregulation 
              ~ = No significance or trend towards deviation from the mean 
 ns  = No statistical significance   
 (p) = Actual p value 
 
Treatment with FGF6 seems to activate the quiescent PHMs to allow them to re-enter 
the cell cycle in all 3 clones, although to a different statistical extent as seen with the 
ki67 proliferation marker. Individual treatment using FGF2 alone did not have a pro-
proliferative effect on the quiescent PHMs, except in one clone which demonstrated a 
trend for increased proliferation. However, viewing the ki67 and p21 data together, it 
appears that FGF2 treatment does not directly promote proliferation but indirectly aids 
in reducing inhibitory mechanisms including the downregulation of p21 when applied 
to the quiescent PHMs. This was the case for all the three clones (Fig 5.12). 
MyoD is a dominant and master myogenesis marker of which neither FGF2 nor FGF6 
regulated MyoD expression consistently: only one clone responded to FGF6 by 
increasing MyoD expression significantly (KH3). FGF6 is proposed to contribute to 
PHM’s activation and this may explain the lack of response in MyoD expression. 
Therefore, FGF6 may potentially be involved only in the early stages of activation and 
proliferation with no significant influence on differentiation. Relative to GAPDH, the 
differential expression of MyoD across all three PHM clones suggests that MyoD might 
have its own internal feedback mechanism. In other words, when it starts low, it is 






When considering the ki67 and myf5 expression, the majority of the response occurs 
together where they were similarly changed or remained unchanged for FGF6 and 
FGF2 following the treatments. myf5 is associated with quiescent satellite cells and as 
an early proliferation marker for myoblasts, therefore upregulation suggests promotion 
of activation of the PHMs. This promotor of activation seemed to proceed further in the 
myogenic pathway for clones KH3 and KH1. In contrast, clone S6.3 clearly had a much 
larger myf5 response and no MyoD response. This suggests an alternate role for myf5, 
perhaps favouring self-renewal. 
With regards to sequential treatments using FGF6 followed by FGF2, data suggests 
that the timing of the treatment would need to be optimised for effective proliferation 
after activation. The 24-hour time period of FGF6 treatment did not seem sufficient for 
completion of the activation sequence of the PHMs in order to facilitate the significant 
effect of subsequent treatment of FGF2. By providing sufficient time after the initial 
treatment, PHMs proliferation could be improved. 
These data suggest that timing and choice of treatment with respect to the state of 
cells is crucial for enhancing activation, proliferation and myogenic function.  
5.7 Conclusion 
The effects of FGF6 or FGF2 alone and sequential combinations of both are 
highly dependent on the source of PHMs.  
FGF6 treatment alone was able to activate and aid in the re-entry of PHMs into the 
cell cycle in quiescent PHM clones of all three subjects. 
FGF2 treatment alone did not promote the activation and re-entry in the cell cycle. 
However, it did inhibit the inhibition factors of proliferation, like p21, which could 
indirectly influence proliferation. This was the case for all three subjects. 
Sequential treatment of FGF6 followed by FGF2 showed promise for significantly 
influencing proliferation, however, did not effectively achieve the hypothesis. This is 
possibly due to the timing of sequential treatment.  
Sequential treatment of FGF2 followed by FGF6 did not seem to have profound effects 
on the activation or proliferation of the quiescent cells. This also indicates the 
sequence of the treatment is crucial to obtain effective activation and improved 





Chapter 6: Discussion 
  The main rationale leading to all the chapters in this thesis was: given that FGF6 
is found predominantly in muscle lineage and early stages of development, it could be 
utilised to activate the quiescent PHMs. Furthermore, sequential treatment with FGF2 
after FGF6 treatment could improve the proliferation rate of PHMs. In order to properly 
investigate the effects of these FGFs, two distinct in vitro quiescence protocols were 
compared. To consider the differences between the PHMs harvested and expanded 
from the different donors, this thesis also set out to establish comparative index to 
compare the PHMs in vitro to each other in order to understand the variability of PHMs 
and the possible variability in response to the treatment with FGFs. 
 
6.1.1 Variability between different PHM populations and rate of proliferation. 
 Rate of proliferation has been studied for a long period of time in cancer studies 
[105-108]. When the first studies defined the four phases of the cell cycle using 
radioactive labelling techniques, it was discovered that not all cells in the population 
proliferate at a similar rate [109]. This causes variability, not only in similar cell types, 
but also in primary cells where the adaption to the environment of the origin of cells 
could have altered the rate at which the cells divide.  In the study performed here 
establishing the comparative index, it was proposed that even though the PHMs were 
obtained for volunteers with similar age and physical activity habits, this index would 
be able to assess the PHMs to determine a basal proliferation characteristic. 
Depending on this index, the PHMs might or might not respond differently after specific 
FGF treatment application in vitro. 
The study design was aimed at assessing the rate of proliferation from G1 to S phase 
and the amount of total RNA synthesised. These two variables provided the baseline 
to compare multiple PHMs to each other. 
The comparative index study showed that up to 10 hours after plating cells from the 
expanded stocks of S6.3 and S9.1, there was no significant transition from G1 to S 
phase (Figure 3.2, 3.4). This could be due to the time required for anchoring and re-
initiating cell metabolism after trypsinisation. Depending on the type of cell, the timeline 





was performed on asynchronized PHMs, the initial lag phase in both the PHMs 
showed exponential increase in transition. However, with the 24 hrs assessed, the S 
phase proportion for S6.3 peaked at 22% at the 22-hour time point and subsequently 
seemed to decrease. S9.1 had not reached the peak proportion at the same time point 
and the S phase proportion was still rising at the 24-hour timepoint. Therefore, this 
experiment identified the differential rate of cell cycle progression between the two 
PHM populations. This testing environment could be used in future for different 
applications, including the application of different treatments to a slower clone to 
increase the rate of proliferation to match that of the faster clones. 
However, RNA concentrations did not require the long lag phase after plating the cells. 
This can be explained as RNA is continually generated even before the initiation of the 
S phase [114]. RNA was seen to increase from the 4 to 6 hour time points and 
increased linearly until the 22-hour time point for S6.3 where it subsequently started 
to decrease. S9.1 however, coincided with the S phase data and kept increasing even 
up to the 24 hour time point.  
The differences between the two clones could indicate that the cells could have had 
adapted according to the niche environment of origin leading to downstream 
consequences on their in vitro culture characteristics. Within each clone, there were 
similar observations when comparing S phase proportion and RNA. 
 
6.1.2 Advantages of establishing a baseline for comparison of cell proliferation. 
Rate of proliferation is the speed at which the cell progresses from one phase 
to the next until cell division. With establishment of a baseline rate of proliferation, 
populations of healthier, actively proliferating cells may be identified. Since the 
characteristics of cells change with higher passage, the baseline can assist in 
identifying more active and younger batches of cells. 
Although the study focussed on PHMs and the transition from G1 to S phase, the same 
concept can be applied to other proliferating cells (for example, C2C12 cells transiting 
from G1 to S, S to G2 or even G2 to M phase). It may be necessary not only to look at 
G1 but all phases during the process of cell division. Although assessment of 





downstream applications. The phase at which the cells are positioned may also assist 
in choosing the right delivery time point for a particular intervention. Here, two 
examples will be given. Firstly, in order for cells to progress through mitosis and create 
two daughter cells, protein synthesis is essential. This step (protein synthesis) initiates, 
typically in the late S phase and G2 phase [115]. Therefore, a treatment aimed at 
promoting this process should not be added earlier. Secondly, myoblasts are cells with 
a high requirement for protein synthesis so the divided cells can prepare adequately 
for subsequent fusion by synthesising not only MRFs but also early sarcomere 
proteins and fusion proteins. In this case treatment could best be applied in G2 phase.  
Rate of proliferation can be assessed using variety of methods. For example, Some 
of these established method include the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) [12] assay which measures the overall metabolic activity 
of the cell using a permeable dye; the intensity of the coloured end product is easily 
detected and measured using a calorimeter. Similarly, WST-1 also is a dye used to 
measure cellular activity which can be used to assess the rate of proliferation. Again, 
this is an indirect method based on intensity of the reaction and colour produced. The 
WST-1 assay works by cleaving tetrazolium salt, MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), in the cell by 
mitochondrial dehydrogenase to produce formazan product (artificial chromogenic 
product) which can further be detected by colorimeter. Higher the number of 
metabolically active cells, higher the formazan product. Fluorescent dyes are also 
used to measure the rate of cellular proliferation providing greater sensitivity and 
precision e.g. eFluor 670 proliferation dye [116], Cell Biolabs’ CytoSelect™ [117-119]. 
The CytoSelect™ works on the principle of incorporating (3H)thymidine into the DNA 
which can further be detected using fluorometric measurements. 
Not all cells during proliferation multiply at the same rate [12]. Assessing the cell count 
over time is the most direct method for estimating rate of proliferation [12]. Cell count 
alone, however, does not provide the sufficient level of details attained from cell cycle 
behaviour. Estimating the proportion of cells in different phases of the cell cycle 






6.1.3 Effects of Rate of proliferation. 
 Rate of proliferation is an important part of cell cycle. The rate at which cell 
divides greatly influences the viability of the cell. Cells are constantly replenished in 
the body although at different rates for different tissues [12]. In the regeneration 
scenario, the quicker the cells proliferate the better it is to restore the damaged tissue 
[12]. However, this also can lead to mutations in the genomic content due to restricted 
time for repairing DNA damage before undergoing DNA replication [64]. With repeated 
accumulation of mutations, the cell could become cancerous in nature [120]. Further, 
cells exposed to these different conditions may exhibit variable rates of proliferation.  
 
6.1.4 Downstream applications of a proliferative/comparative index (CI)  
In the area of regenerative medicine, transplantation of cells is moving towards 
becoming a more common practice in personalised treatments than a decade ago 
[12]. A comparative index could assist in choosing the best batch of cells possible for 
the treatment. With autologous transplantation, help of proliferative agents such as 
FGF2 can also be incorporated to enhance the proliferative capacity of the cells to 
multiply faster in vitro before transplanting, resulting in quicker turnaround to help 
regeneration. Also, identifying the ideal delivery time point according to 
synchronization and cell cycle phase may prove to be important in future. 
In the field of cancer studies, some of the chemotherapeutic drugs act according to 
the rate of proliferation rather than the mutation. The rate of cell division is targeted, 
and cell cycle phase is recognised by the drug. This creates a “proliferation rate 
paradox” [120]. In future, the comparative index such as described in this thesis could 
help identify cells that have acquired mutations and proliferate at a different rates. 
Either reprograming or applying a treatment to such cells to improve their proliferation 
rate, could then be checked for efficacy using CI. Reprogrammed ultimately the drug 
may need to act on specific cells with different rate of proliferation. 
In contrast, slower dividing cells could be used further for in vitro studies in order to 






6.1.5 Achieving effective quiescence in vitro. 
Initiating induction of quiescence from a state of activation one can study the 
feedback mechanisms utilised to induce quiescence. Achieving effective in vitro 
quiescence in a limited amount of time could assist in understanding specific early 
aspects of skeletal muscle regeneration such as activation. Here effective quiescence 
was considered to be achieved when the expression of ki67 was lower compared to 
the proliferating cells. PHM re-entry into the cell cycle following activation is crucial for 
assessing effective quiescence induction, because it would indicate that no permanent 
negative effects were caused, such as senescence. 
In chapter 4, PHMs were subjected to SuCu KOSR for 48 hours, the levels of cyclin 
genes’ expression were down regulated significantly, more importantly, cell cycle shift 
was observed towards reduced proliferation resulting in achievement of cellular 
quiescence. A similar protocol was used by Sellathurai et al, (2013) wherein ki67 and 
p21 mRNA expression in PHMs treated with SuCu FBS were assessed. Similar to the 
current study, ki67 was downregulated while p21 was upregulated in suspension 
media [43].  
 
6.1.6 State of quiescence 
 Understanding of the G0 phase which can sometimes be viewed either as an 
extension of G1 phase or an individual state outside of the repetitive cell division cycle, 
plays an important role in understanding cell cycle. With the timeline of G1 phase being 
diverse, even within the same tissue but different cells [121, 122] understanding the 
transition from G0-G1 is essential. Transcriptomes of various types of stem cells which 
reside in quiescent states exhibit downregulation of important cell cycle genes such 
as cyclin A2, B1 and E2 [90, 123]. However, even during the quiescent state some of 
the genes relating to stem cell fate are upregulated e.g. FOXO3 and EZH1 [90]. In 
Chapter 4, where multiple in vitro quiescence protocols were tested, the induction of 
quiescence was seen with the downregulation of cell cycle genes. Although the 
expression of genes such as ki67 and myf5 were significantly downregulated, it still 
does not mean complete arrest of the molecular function. This was confirmed by 
continued expression of total RNA. In vitro the duration of quiescence poses more 





quiescence has halted cell cycle progression? Additionally, does the state of 
quiescence differ in PHM clones from different donors? 
 
6.1.7 Mechanism of G0 exit. 
 Cyclin C and retinoblastoma(Rb) protein have been shown to be involved in the 
G0 exit and G1-S phase re-entry by hyperphosphorylation of Rb [124-126]. In 
mammalian cells, cyclin C mRNA is found to be at elevated levels at the time of cell 
cycle re-entry suggesting their involvement in Rb phosphorylation [127, 128]. 
Furthermore, the activity of Rb was found to be lower during the G1-S phase transition 
compared to early G1 phase. This suggests that the involvement of Rb is more 
important during G0-G1 transition. The E2F family, playing a major role in G1/S phase 
transition, is involved in the coding of multiple transcription factors [129-132] and has 
been shown to be active resulting in the activation of the necessary genes such as 
CCNA1,2 CCND1,2 by recruiting histone acetyltransferase, essential for the G1 entry 
[128]. In a study performed by Armand et al (2003) [133] it was demonstrated that, the 
injection of recombinant FGF6 in the soleus muscle for regeneration in a FGF6(-/-) 
mice, cyclin D1 was upregulated with downregulation of calcineurin [64]. In future in 
vitro studies, these additional regulators could be assessed at different time points 
after FGF6 treatment in quiescent cells. For example, the effect of cyclin C can further 
be confirmed by in vitro experiments such as knockdown and over expression in the 
state of quiescence and early activation. 
6.1.7.1 The importance of restriction point in exit from G0 
 Restriction point or R-point in the cell cycle is referred to the point of 
commitment towards DNA synthesis and cell division (before S phase). During the exit 
from quiescence the cell requires extracellular stimulation to initiate the progression, 
during the third subphase of G1, the cell commits to the DNA replication process after 
which the stimulation is not required. The withdrawal of the stimulants before the 
commitment could result in cell’s revision to quiescence. Under reversal conditions the 
cell might need additional time to restart the re-entry process known as withdrawal 
time which can be about 8 hours which can be clearly seen in the figure 3.2 and 3.4. 





phase during the first 10-12 hours due to trypsinisation which resets the withdrawal 
time. 
 
6.1.8 FGFs: A family performing individual tasks. 
 FGFs with four FGF receptors act on various aspects of tissue synthesis [45, 
134, 135]. Although the 22-member family is critically involved in embryonic growth as 
shown by knockout studies [136, 137], the role involving each FGF in the adult tissue 
needs to be probed. 
With respect to myoblasts in the adult process of myogenesis, various FGFs play a 
crucial role in specific aspects of the process. The data presented here indicate that 
FGF6 is involved in activation of the quiescent satellite cells initiating the cascade of 
events which when followed with FGF2 helped in proliferation of the activated PHMs. 
Other FGFs may also assist in the differentiation of the cells promoting fusion [138, 
139]. 
The current study using PHMs found that FGF6 and FGF2 both promoted activation 
and proliferation of quiescent PHMs but do so by adapting different regulating factors. 
This included a greater increase in ki67 expression with FGF6 than FGF2. This could 
be explained by the activation of the Cdk complex, which could be investigated in 
future studies. To determine if specific FGF receptors may play a role, receptor 
blockade could prove to be informative.  
A second regulatory effect was reduction in the expression of p21. Specifically, FGF2  
downregulated the inhibitory checkpoint of p21 which could indirectly allow PHM’s 
activation. FGF2 is known to be an upstream initiator of the MAPK pathway [140, 141]. 
By releasing Cks1, FGFR substrate 2 [142] recruits downstream molecules for 
signalling and is ultimately associated with downregulation of p27. During the late 
mitosis phases, M-Cdk is inactivated by Cdc20-APC (tumour suppressor protein). 
However, Cdc20-APC is also stimulated by M-Cdk. The loss of M-cyclin in the late 
mitosis phase inactivates all APC activity. Completion of cell division, the cell starts 
accumulating M-cyclin for the next cycle in G1, which assists in G1-S phase transition 
during cell cycle [85]. Activation of the Cdk complex is achieved when the cyclin-





regulates the transcription factors and production of mRNA [143, 144]. In future 
studies, the observed changes in total RNA should be analysed in more detail, 
possibly using microarray. 
In the case of muscle regeneration, without a considerable number of proliferative 
myoblasts in the injured muscle niche, treatment with FGF2 might not be ideal for 
regeneration. Since the rate of proliferation increases with active cells and FGF6 
induces activation of quiescent PHMs, a  combination treatment could therefore 
provide effective support for the sequence of regeneration. With the rapid increase in 
the S phase with the treatment of FGF6 in all three PHMs clones assessed in this 
thesis, the data suggest that FGF6 should be used first in the sequence as an 
activation agent (Figure 5.2). Also, FGF2 induced progression from S phase to G2 
phase and this suggests that it should be applied second in the sequence.  
The cell cycle data were supported by the qPCR analysis of the PHMs. FGF6 
treatment increased ki67 and decreased p21 expression (Figure 5.9, 5.11). In 
contrast,FGF2 treatment had no effect on ki67 (Fig 5.10) but similarly decreased p21 
expression. These results collectively suggest that the treatment with FGF6 and FGF2 
could also be beneficial together and not just sequentially. Future studies should test 
this sequence in an in vivo model of injury regeneration. 
 
6.1.9 Using FGF6 along with FGF2 could enhance regeneration of skeletal 
muscle. 
 Activation of satellite cells in vivo is a tightly orchestrated process after injury. 
Upon injury, activation signals are released which in turn activate the quiescent 
satellite cells. In a study mentioned in the introduction, FGF6 was upregulated when 
skeletal muscle tissue was damaged [69]. The data of this thesis indicated under 
controlled conditions that FGF6 activated the quiescent PHMs (chapter 5). However, 
FGF6 could also have an effect on proliferation mediated by ERK, MAPK [61] as it has 
been shown in a recent study how cells, such as osteoblasts and osteoclasts, both 
respond by proliferating [65]. We propose that the same mechanism of action in 
osteoblasts could also be applicable in satellite cells. Hence, treatment with FGF6 with 
FGF2 could potentially enhance regeneration initiating from activation by FGF6 and 






6.1.10 Implementing comparative index (CI) after interventions with FGFs. 
CI could be used widely to compare different kinds of cells, different treatments 
or even the same cells prior to and post intervention. Establishing an index reference 
bank can help in different ways. Primarily, this thesis suggests its usefulness to assess 
the functionality of PHM explants from different individuals so that they could be 
compared to a CI in a reference data bank from known robust stocks. CI could also be 
used to distinguish between fast and slow proliferating cells in process other than 
myogenesis, such as cancer studies where the rate of proliferation is an important part 
of diagnosis.  
Once CI is established for G0/G1 to S phase, one could also similarly develop an index 
to compare the rate of cell cycle through other phase transitions. FGF2 is ineffective 
when the majority of cells are in G0/G1 phase(Chapter 5.10), however when the cells 
progress through to S / G2 phase, FGF2 treatment could have a significant effect on 




 These studies were performed on PHMs. As discussed earlier, PHMs may have 
different behaviour that might produce different results for similar experiments when 
performed on PHMs harvested from different donors. 
CI was established and tested on two different PHM explants. This needs to be tested 
on a larger number of samples to verify and to create the proposed “reference bank”. 
Limited number of PHMs might be providing narrow range of outcomes. Increasing the 
number of different PHMs could help attain a better understanding and the variance 
between PHM clones could be estimated. CI could also be used on an immortalised 
cell line such as C2C12, where the proliferation rate should remain stable with 
relatively low passage numbers, in order to verify repeatability.  
The treatments of FGFs were performed in vitro which follows a linear path, these 





of other events that might affect the treatments could alter the outcome. Animal model 
tests would provide better indication of the in vivo effects. 
6.3 Future recommendations: 
6.3.1 Establishing an improved bridged protocol. 
The SuCu achieved quiescence in 48 hours. However, soon after harvesting 
the PHMs get activated. Nevertheless, with the establishment of the bridged protocol, 
this thesis opened up a new avenue that could be taken further. For example, 
combining SuCu-KOSR and the KOSR techniques could establish a stable protocol to 
induce quiescence in vitro. A combined and improved bridged protocol could have the 
SuCu for the first 48 hours and upon harvesting, the PHMs could be plated in KOSR 
medium potentially attaining quiescence shortly after replating in KOSR media. The 
proposed improvement of using the SuCu protocol followed by KOSR is that, the whole 
10 days required to initiate quiescence with KOSR alone, would be shortened 
significantly. This provides all the benefits of KOSR protocol without the disadvantages 
of SuCu. 
 
6.3.2 Comparative index 
 CI could use the comparison not only between different PHMs but also between 
different cell lines providing an insight on the ratio of rate of proliferation between 
different cell types in tissue. However, it needs to be assessed in detail how different 
cells respond to the 24hr protocol. Also comparing an immortalised cell line (C2C12) 
to PHMs could provide a better insight on how similar they are to PHMs of healthy 
donors. 
 
6.3.3 In vivo treatment with FGF6 and or FGF2 
With the effects of FGF6 and FGF2 now established in vitro, applied to a  
quiescence state, a similar protocol can be constructed to be assessed in animal 
models. The effect of the treatment once administered in vivo can be tracked over 





/ proliferation. Staining markers such as pax7, PCNA, myf5, MyoD and myogenin can 
be included in the assessment. 
In vitro studies follow a linear pathway of assessment, such as the effect of the only 
treatment administered. In the in vivo environment there is cascade of events 
occurring which might intervene/influence with the administered treatment. The whole 
response might still be a positive influence even if slightly different. 
The mechanisms involved in pro-activation and anti-inhibition of cell cycle progression 
need to be probed in PHMs in more detail. This could give a vital understanding of the 
role of two different FGFs for combination or sequential treatments. 
 
6.3.4 Overview of incorporating comparative index and FGF treatments 
The comparative index provides the different rate of progression in various 
phases of the cell cycle. With sufficient samples processed for different clones and 
testing the dose response with FGF could help plot a curve with rate of progression 
and dosage of FGF. This can be utilized in determining the dose response as a 
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Table A3.3 Mean data of S phase and total RNA between S6.3 and S9.1 







S Phase  
(%) 








02  3.73 4704.00  02  1.41 2312.00 
04  2.32 5032.00  04  1.35 2174.67 
06  2.39 5440.00  06  1.39 2648.00 
08  2.45 5448.00  08  1.49 2690.67 
10  3.37 6073.33  10  1.98 3104.00 
12  3.98 5209.33  12  2.38 3741.33 
14  5.91 6384.00  14  4.32 4585.33 
16 7.11 7133.33  16  5.20 5150.67 
18  11.08 8006.67  18  6.03 5524.00 
20  15.43 8292.00  20  10.63 6014.67 
22  22.74 8933.33  22  11.15 6418.67 
24  21.16 7946.67  24  13.68 6674.67 
 
Table A3.4 Raw data for method 2 B for calculating comparative index 










  (%) (ng)   (%) (ng) 
Timepoints     Timepoints     
(hr)     (Hr)     
12 3.98 5209.33 12.00 2.38 3741.33 
14 5.91 6384.00 14.00 4.32 4585.33 
16 7.11 7133.33 16.00 5.20 5150.67 
18 11.08 8006.67 18.00 6.03 5524.00 
20 15.43 8292.00 20.00 10.63 6014.67 
22 22.74 8933.33 22.00 11.15 6418.67 
24 21.16 7946.67 24.00 13.68 6674.67 
 







for S  phase 
Trepezoid Areas 
for total RNA   
Trepezoid 
Areas for S   
Trepezoid 
Areas for 
RNA   
9.89 11593.33 6.70 8326.66 
13.02 13517.33 9.52 9736.00 
18.19 15140.00 11.23 10674.67 
26.51 16298.67 16.66 11538.67 
38.17 17225.33 21.78 12433.34 
43.90 16880.00 24.83 13093.34 
        
149.68 90654.66 90.72 65802.68 
 
Table A5.1 Cell cycle analysis data of Subject S6.3, KH 3 and KH 1, Quiescence vs 
Quiescence + FGF2 




  G1% S % G2 % 
 
G1% S % G2 % 
N1 86.46 1.13 12.41 
 
86.06 1.68 12.26 
N2 86.73 1.36 11.92 
 
83.70 0.96 15.33 
N3 86.22 1.70 12.08 
 
82.75 1.21 16.06 
KH 3 cells Quiescence 
 
QF2 
  G1% S % G2 % 
 
G1% S % G2 % 
N1 87.28 3.31 9.41 
 
85.95 2.68 11.37 
N2 88.68 3.59 7.73 
 
86.41 2.59 11.01 
N3 85.54 3.69 10.77 
 
83.69 2.58 13.73 
KH 1 cells Quiescence 
 
QF2 
  G1% S % G2 % 
 
G1% S % G2 % 
N1 91.48 2.89 5.63 
 
89.73 2.15 8.12 
N2 90.16 2.77 7.07 
 
88.47 2.44 9.10 
N3 91.44 2.88 5.68   87.58 2.77 9.65 
 
 
Table A5.2 Cell cycle analysis data of Subject S6.3, KH 3 and KH 1, Quiescence vs 









  G1% S % G2 % 
 
G1% S % G2 % 
N=1 87.15 5.54 7.31 
 
76.12 21.1 2.78 
N=2 86.2 5.84 7.96 
 
77.95 18.12 3.93 
N=3 88.16 5.17 6.68 
 
77.17 20.95 1.89 
  
      
  
KH 3 cells Quiescence 
 
QF6 
  G1% S % G2 % 
 
G1% S % G2 % 
N=1 86.45 3.94 9.61 
 
77.42 17.68 4.9 
N=2 88.94 4.13 6.93 
 
77.72 19.48 2.8 
N=3 87.19 4.57 8.24 
 
78.65 18.17 3.18 
  
      
  
KH 1 cells Quiescence 
 
QF6 
  G1% S % G2 % 
 
G1% S % G2 % 
N=1 90.19 3.79 6.02 
 
76.11 18.43 5.46 
N=2 91.01 3.84 5.15 
 
75.49 20.55 3.96 









































4.3 S phase % 7.28 
  G2 % 8.71 G2 % 7.5 








4.01 S phase % 9.47 
  G2 % 7.35 G2 % 5.96 








4.3 S phase % 8.49 
  G2 % 8.02 G2 % 6.63 
   
   
Quiescent 
Mean 














4.20 -0.10  S phase % 8.41 1.13 100.16 






































  G1 % 87.15 G1 % 76.12 
  S phase % 5.54 S phase % 21.1 
  G2 % 7.31 G2 % 2.78 




  G1 % 86.2 G1 % 77.95 
  S phase % 5.84 S phase % 18.12 
  G2 % 7.96 G2 % 3.93 




  G1 % 86.56 G1 % 76.53 
  S phase % 5.96 S phase % 20.6 
  G2 % 7.48 G2 % 2.87 










Stats G1 % 86.64 -0.51 G1 % 76.87 0.75 -11.28 




  G2 % 7.58 0.27 G2 % 3.19 0.41 -57.89 
 
 
 
 
 
 
 
Stellenbosch University https://scholar.sun.ac.za
